

## AUTHOR INDEX

**Page references to supplement 1 (April 1995) are preceded by S1:**

- |                        |                         |                            |
|------------------------|-------------------------|----------------------------|
| Abdel-Khadir, A., 40   | Brunner, F., 242        | Desmeules, M., 134         |
| Agodoa, L. Y., 119     | Brunner, W., 242        | Deubner, H., 330           |
| Ahlfors, C. E., 543    | Bry, W. L., 543         | De Vol, E., 572            |
| Ahmed, Z., 269         | Buck, C., 262           | Disney, A. P. S., 165      |
| Akmal, M., 440         | Buddington, B., 314     | Domoto, D., 648            |
| Al Ahdal, M., 572      | Bunchman, T. E., 17     | Dressler, R., 346          |
| Alamo, C., 340         | Bunke, M., 769          | Duarte, G., 465            |
| Alexiewicz, J. W., 440 | Burger, H.-R., 242      | Duarte, R., 40             |
| Alfrey, A. C., 314     | Burgess, K. M., 228     | Dussol, B., 399            |
| Alfurayh, O., 572      | Burns, E. R., 801       |                            |
| Ali, A., 572           | Butani, L., 489         | Edefonti, A., 222          |
| Alley, P. A., 543      | Buzelin, F., 486        | Edmonds, J., 235           |
| Al Meshari, K., 572    |                         | Edward, N., 276            |
| Alpers, C. E., 330     | Cantú, T. G., 228       | Eggers, P. W., 119         |
| Andrassy, K., 336      | Cardinal, J., 761       | Elivera, H. S., 269        |
| Appel, R. G., 207      | Catto, G. R. D., 276    | Ellis, A., 222             |
| Araque, A., 340        | Chaballout, A., 40      | Ettenger, R. B., 46        |
| Arbeit, L., 75         | Chang, J. J., 297       |                            |
| Arbus, G., 134         | Chang, P. C., 370       | Fahrenkamp, A., 775        |
| Assmann, K. J. M., 781 | Chen, K.-S., 694        | Falardeau, M., 761         |
| Azzani, T., 222        | Cheung, A. T. W., 543   | Feeny, D. H., 548          |
|                        | Chihara, K., 637        | Fenton, S., 134            |
| Baba, S., 405          | Choudhury, D., 269      | Ferraz, A. S., 465         |
| Babazono, T., 151      | Chu, S.-H., 694         | Feucht, H. E., 253, 291    |
| Babcock, S., 26        | Clark, W. F., 320       | Fine, A., 498              |
| Baker, P. L., 26       | Cody, R. P., 579        | Finger, M., 346            |
| Ball, D., 269          | Collins, A. J., 281     | Finkelstein, F. O., 461    |
| Banisadr, B., 486      | Cologna, A. J., 465     | Fishbane, S., 34, 346, 426 |
| Barash, B. D., 302     | Compton, A., 22         | Fjermers, G., 597          |
| Barba, L., 46          | Conger, J. D., 96       | Flack, J. M., 281          |
| Barrientos, A., 30     | Conte, F., 196          | Fleming, S., 498           |
| Bechtel, U., 253, 291  | Contiguglia, R., 26     | Florijn, K. W., 370        |
| Bennett, P. H., 107    | Cooper, M. A., 314      | Foley, R. N., S1:3         |
| Bennett, W. M., 63     | Copleston, P., 134      | Folkert, V. W., 801        |
| Benz, R. L., 548       | Corghi, E., 222         | Fontanellas, A., 30        |
| Berger, C., 262        | Coronel, F., 30         | Foote, E. F., 420          |
| Berland, Y., 399       | Cortez, M. S., 632      | Fornasieri, A., 361        |
| Berthezène, P., 399    | Costa, J. A. C., 465    | Freedman, B. I., 207, 710  |
| Bianchi, G., 222       | Cowley, B. D., Jr., 302 | Frei, G. L., 34, 346       |
| Bolton, W. K., 632     | Cox, K. L., 543         | Friedlander, M. A., 445    |
| Bolz, K.-D., 597       | Csernok, E., 253        | Friedman, E. A., 390, 689  |
| Borok, R. Z., 534      | Csete, M., 629          | Fritsche, C., 603          |
| Braden, G. L., 611     | Custer, J. R., 17       | Froment, D., 134           |
| Brancati, F. L., 722   |                         | Fryback, G., 701           |
| Brandes, J. C., 603    | Dalquen, P., 242        | Fujita, Y., 67             |
| Brathwaite, M., 798    | D'Amico, G., 113, 361   | Fukase, M., 637            |
| Brazy, P. C., 701      | Danovitch, G. M., 46    | Furuhashi, M., 807         |
| Breuning, J. H., 370   | Dash, A., 380           |                            |
| Brier, M. E., 769      | Daugirdas, J. T., 810   | Garcia, T. M. P., 465      |
| Brignol, F., 801       | Dell'Antonio, G., 222   | Gardner, D. F., 798        |
| Brown, E., 461         | Delmez, J. A., 1        | Gardner, K. D., Jr., 357   |
| Brown, E. M., 506      | Demetron, G., 642       | Gaskin, G., 380            |
| Brown, M. A., 235      | De'Oliviera, J., 380    | Gattone, V. H., II, 302    |
| Brown, R. E., 548      | De Salamanca, R. E., 30 | Gerhardt, R. E., 343       |
| Brunet, P., 399        | DeSalles, A., 629       | Germain, M. J., 611        |

## AUTHOR INDEX

**Page references to supplement 1 (April 1995) are preceded by S1:**

- |                        |                         |                            |
|------------------------|-------------------------|----------------------------|
| Abdel-Khadir, A., 40   | Brunner, F., 242        | Desmeules, M., 134         |
| Agodoa, L. Y., 119     | Brunner, W., 242        | Deubner, H., 330           |
| Ahlfors, C. E., 543    | Bry, W. L., 543         | De Vol, E., 572            |
| Ahmed, Z., 269         | Buck, C., 262           | Disney, A. P. S., 165      |
| Akmal, M., 440         | Buddington, B., 314     | Domoto, D., 648            |
| Al Ahdal, M., 572      | Bunchman, T. E., 17     | Dressler, R., 346          |
| Alamo, C., 340         | Bunke, M., 769          | Duarte, G., 465            |
| Alexiewicz, J. W., 440 | Burger, H.-R., 242      | Duarte, R., 40             |
| Alfrey, A. C., 314     | Burgess, K. M., 228     | Dussol, B., 399            |
| Alfurayh, O., 572      | Burns, E. R., 801       |                            |
| Ali, A., 572           | Butani, L., 489         | Edefonti, A., 222          |
| Alley, P. A., 543      | Buzelin, F., 486        | Edmonds, J., 235           |
| Al Meshari, K., 572    |                         | Edward, N., 276            |
| Alpers, C. E., 330     | Cantú, T. G., 228       | Eggers, P. W., 119         |
| Andrassy, K., 336      | Cardinal, J., 761       | Elivera, H. S., 269        |
| Appel, R. G., 207      | Catto, G. R. D., 276    | Ellis, A., 222             |
| Araque, A., 340        | Chaballout, A., 40      | Ettenger, R. B., 46        |
| Arbeit, L., 75         | Chang, J. J., 297       |                            |
| Arbus, G., 134         | Chang, P. C., 370       | Fahrenkamp, A., 775        |
| Assmann, K. J. M., 781 | Chen, K.-S., 694        | Falardeau, M., 761         |
| Azzani, T., 222        | Cheung, A. T. W., 543   | Feeny, D. H., 548          |
|                        | Chihara, K., 637        | Fenton, S., 134            |
| Baba, S., 405          | Choudhury, D., 269      | Ferraz, A. S., 465         |
| Babazono, T., 151      | Chu, S.-H., 694         | Feucht, H. E., 253, 291    |
| Babcock, S., 26        | Clark, W. F., 320       | Fine, A., 498              |
| Baker, P. L., 26       | Cody, R. P., 579        | Finger, M., 346            |
| Ball, D., 269          | Collins, A. J., 281     | Finkelstein, F. O., 461    |
| Banisadr, B., 486      | Cologna, A. J., 465     | Fishbane, S., 34, 346, 426 |
| Barash, B. D., 302     | Compton, A., 22         | Fjermers, G., 597          |
| Barba, L., 46          | Conger, J. D., 96       | Flack, J. M., 281          |
| Barrientos, A., 30     | Conte, F., 196          | Fleming, S., 498           |
| Bechtel, U., 253, 291  | Contiguglia, R., 26     | Florijn, K. W., 370        |
| Bennett, P. H., 107    | Cooper, M. A., 314      | Foley, R. N., S1:3         |
| Bennett, W. M., 63     | Copleston, P., 134      | Folkert, V. W., 801        |
| Benz, R. L., 548       | Corghi, E., 222         | Fontanellas, A., 30        |
| Berger, C., 262        | Coronel, F., 30         | Foote, E. F., 420          |
| Berland, Y., 399       | Cortez, M. S., 632      | Fornasieri, A., 361        |
| Berthezène, P., 399    | Costa, J. A. C., 465    | Freedman, B. I., 207, 710  |
| Bianchi, G., 222       | Cowley, B. D., Jr., 302 | Frei, G. L., 34, 346       |
| Bolton, W. K., 632     | Cox, K. L., 543         | Friedlander, M. A., 445    |
| Bolz, K.-D., 597       | Csernok, E., 253        | Friedman, E. A., 390, 689  |
| Borok, R. Z., 534      | Csete, M., 629          | Fritzsche, C., 603         |
| Braden, G. L., 611     | Custer, J. R., 17       | Froment, D., 134           |
| Brancati, F. L., 722   |                         | Fryback, G., 701           |
| Brandes, J. C., 603    | Dalquen, P., 242        | Fujita, Y., 67             |
| Brathwaite, M., 798    | D'Amico, G., 113, 361   | Fukase, M., 637            |
| Brazy, P. C., 701      | Danovitch, G. M., 46    | Furuhashi, M., 807         |
| Breuning, J. H., 370   | Dash, A., 380           |                            |
| Brier, M. E., 769      | Daugirdas, J. T., 810   | Garcia, T. M. P., 465      |
| Brignol, F., 801       | Dell'Antonio, G., 222   | Gardner, D. F., 798        |
| Brown, E., 461         | Delmez, J. A., 1        | Gardner, K. D., Jr., 357   |
| Brown, E. M., 506      | Demetron, G., 642       | Gaskin, G., 380            |
| Brown, M. A., 235      | De'Oliviera, J., 380    | Gattone, V. H., II, 302    |
| Brown, R. E., 548      | De Salamanca, R. E., 30 | Gerhardt, R. E., 343       |
| Brunet, P., 399        | DeSalles, A., 629       | Germain, M. J., 611        |

- Giles, P., 420  
 Gispaa, I., 46  
 Glickman, J. D., 343  
 Golper, T. A., 769  
 Gorban-Brennan, N., 461  
 Grantham, J. J., 302, 471  
 Gretch, D. R., 67, 798  
 Grist, T. M., 701  
 Grolleau, J.-Y., 486  
 Gross, W. L., 253  
  
 Haffner, S., 107  
 Hakim, R. M., 433, 555  
 Halstenson, C. E., 420  
 Hamaguchi, K., 492  
 Hamidou, M. A., 486  
 Harnett, J. D., S1:3  
 Hasbargen, J. A., 297  
 Hatlinghus, S., 597  
 Hébert, M.-J., 761  
 Hebert, S. C., 506  
 Heidenreich, S., 775  
 Held, E., 291  
 Henry, D., 548  
 Herrero, J. A., 30  
 Herzog, C. A., 281  
 Hewett, J. E., 616  
 Hirata, K., 680  
 Hiroshige, K., 413  
 Hishida, A., 807  
 Hoehn-Saric, E. W., 228  
 Holub, B. J., 320  
 Hosaka, E., 492  
 Houde, M., 761  
 Hrboticky, N., 564  
 Hricik, D. E., 445  
 Huang, C.-C., 694  
 Hübel, E., 751  
 Huff, M. W., 320  
 Hugo, J. P., 343  
 Huraib, S., 40  
  
 Ikegaya, N., 807  
 Inenaga, T., 405, 589  
 Ing, T. S., 810  
 Ingram, A. J., 320  
 Inoue, Takashi, 589  
 Inoue, Takuya, 405, 589  
 Inuma, H., 67  
 Ishikawa, I., 151  
 Iskandar, S. S., 207  
 Ismail, N., 433  
 Itagaki, I., 555  
  
 Jacobs, C., 188  
 Jacobs, M., 629  
 Jacobson, H. R., 103  
 Jeffery, J., 134  
 Jago, P., 486  
 Johnson, R. J., 67  
 Jones, E., 176  
 Juergensen, P., 461  
  
 Jung, K., 584  
  
 Kabashima, N., 413  
 Kaizuka, M., 67  
 Kaneko, E., 807  
 Kanwar, Y. S., 680  
 Kashitani, T., 680  
 Kasiske, B. L., 107  
 Kaskel, F. J., 75  
 Kawamoto, K., 637  
 Kawano, Y., 405, 589  
 Keane, W. F., 107, 420  
 Kent, G. M., S1:3  
 Kershaw, D. V., 17  
 Kessie, G., 572  
 Khan, I. H., 276  
 Kiefer, T., 751  
 Kiernan, L., 461  
 Kim, J. K., 58  
 Kimura, G., 405, 589  
 Kirschbaum, B., 22  
 Kiss, D., 242  
 Kjellstrand, C., 134  
 Klag, M. J., 722  
 Klahr, S., 1  
 Klein, M., 26  
 Kliger, A. S., 461  
 Klin, M., 440  
 Kobayashi, S., 807  
 Kobayashi, T., 637  
 Koene, R. A. P., 781  
 Koenigsberg, M., 801  
 Koethe, J. D., 343  
 Kong, N. C. T., 63  
 Korbet, S. M., 534  
 Koshikawa, S., 151  
 Kowalski, E. J., 34  
 Kuhlmann, U., 751  
 Kuroiwa, A., 413  
 Kurtin, P. S. S1:8  
  
 Lai, M.-K., 694  
 Lal, S. M., 616  
 Langman, C. B., 792  
 Lapierre, S. T., 738  
 Larranaga, J., 70  
 Laurence, R. A., 738  
 Lawrence, W. F., 701  
 Lee, E. J. C., 503  
 Lee, J., 269  
 Lehmann, K., 82  
 Leichtman, A. B., 623  
 Leong, S.-O., 503  
 Leslie, W., 498  
 Leu, M.-L., 694  
 Levin, N. W., S1:1  
 Lew, S. Q., 642  
 Limido, A., 196  
 Lin, J.-J., 75  
 Lipkowitz, G. S., 611  
 Llach, F., 663  
 Locatelli, F., 196  
  
 Lonati, F., 196  
 Look, Z. M., 420  
 Lopes, A. A. S., 350, 714  
 Lorenz, R., 564  
 Lund, G. B., 732  
 Lye, W.-C., 503  
 Lynn, B., 555  
 Lynn, R. I., 426  
  
 Ma, J. Z., 281  
 MacLeod, A. M., 276  
 Madden, R. L., 611  
 Maeda, K., 151  
 Magil, A. B., 375, 478  
 Makino, H., 680  
 Malberti, F., 196  
 Mallick, N. P., 176  
 Marcelli, D., 196  
 Markowitz, G. S., 801  
 Martin, K. J., 1  
 Maruyama, Y., 807  
 Massry, S. G., 440  
 Matsuoka, H., 405, 589  
 Mauger, E. A., 623  
 Maxvold, N. J., 17  
 Mendley, S. R., 792  
 Messana, J., 262  
 Mettang, T., 751  
 Mihatsch, M. J., 242  
 Miller, F., 75  
 Miller, J. M., 642  
 Miller, N. L., 314  
 Milliner, D. S., 489  
 Moch, H., 242  
 Mogensen, C. E., 107  
 Monnier, V. M., 445  
 Mooraki, A., 461  
 Moran, M. J., 30  
 Moreau, A., 486  
 Morgenstern, B. Z., 489  
 Morioka, S., 680  
 Mrowka, C., 253  
 Mücke, C., 291  
 Mughal, T., 40  
 Mulhern, J. G., 611  
  
 Nagao, S., 302, 471  
 Nakamura, S., 405, 589  
 Nakazawa, R., 492  
 Nast, C. C., 46  
 Neugarten, J., 515  
 Newsome, J., 262  
 Niederberger, M., 58  
 Nihei, H., 151  
 Nolin, L., 761  
 Noteboom, W. M. P., 370  
 Ntoso, K. A., 343  
  
 Oberholzer, M., 242  
 Ojo, A. O., 623  
 Omac, T., 405, 589  
 Onodera, K., 67

- Opsahl, J. A., 281  
 Osawa, H., 67  
 O'Shea, M. H., 611  
 Ota, K., 151  
 Ota, Z., 680  
 Ouimet, D., 761  
 Packard, W. J., 603  
 Paganini, E. P., S1:12  
 Palazzi, P., 222  
 Parbtani, A., 320  
 Parfrey, P. S., S1:3  
 Parker, R. A., 433  
 Parving, H.-H., 107  
 Passlick-Deetjen, J., 452, 751  
 Perneger, T. V., 722  
 Perry, E., 262  
 Petroski, G. F., 616  
 Pham, P.-T., 642  
 Philbrick, D. J., 320  
 Pichette, V., 761  
 Pollak, M., 506  
 Port, F. K., 350, 623, 714  
 Poznanski, A. K., 792  
 Praga, M., 340  
 Prager, J. P., 629  
 Pusey, C. D., 380  
 Pyo, H.-J., 58  
 Quigg, R. J., 798  
 Racusen, L., 228  
 Rafiq, M., 810  
 Rahn, K. H., 775  
 Rao, T. K. S., 390, 689  
 Rees, A. J., 380  
 Reiter, L., 235  
 Revicki, D. A., 548  
 Rinehart, A. L., 281  
 Ritz, E., 82, 336, 452  
 Roberts, A. B., 269  
 Rodby, R. A., 88  
 Rogers, M. E., 579  
 Rosekrans, J. A., 489  
 Ross, G., Jr., 616  
 Roth, D., 3  
 Roubicek, C., 399  
 Ruddy, S., 798  
 Rudnick, M. R., 548  
 Rutecki, G. W., 70  
 Rydel, J. J., 534  
 Saber, L. T. S., 465  
 Said, R., 40  
 Salinas-Madrigal, L., 648  
 Saltzberg, S. N., 651  
 Sanai, T., 405  
 Sánchez, R., 340  
 Sasaki, T., 67  
 Sato, A., 67  
 Sbeih, F., 40  
 Scheel, P. J., 228  
 Scheel, P. J., Jr., 732  
 Scheiffler, A., 584  
 Scheithe, R., 564  
 Schenk, U., 751  
 Schiff, H., 291, 564  
 Scholz, M., 584  
 Schreiner, G. F., 1  
 Schrier, R. W., 58  
 Schulak, J. A., 445  
 Schulz, Th., 564  
 Schulze, B.-D., 584  
 Schwartz, M. M., 88, 534, 651  
 Sedman, A. B., 17  
 Segasothy, M., 63  
 Selwood, N. H., 176, 188  
 Sepulveda, P., 30  
 Shaffer, D., 593  
 Sherman, R. A., 579  
 Shikata, K., 680  
 Shinoda, A., 151  
 Shishido, H., 492  
 Siebels, M., 336  
 Silbiger, S. R., 346, 515  
 Sitter, T., 291  
 Smorgorzewski, M., 440  
 Solanchick, J. C., 579  
 Sonoda, T., 151  
 Spanner, E., 320  
 Spargo, B. H., 792  
 Spiegel, D. M., 26  
 Spoendlin, M., 242  
 Sponsel, H., 96  
 Spotti, D., 196  
 Spray, B. J., 710  
 Sreedhara, R., 555  
 Steffes, M. W., 107  
 Striker, G. E., 103, 107, 660  
 Sturgill, B. C., 632  
 Sullivan, S., 40  
 Summer, S. N., 58  
 Swaminathan, M., 63  
 Swartz, R., 262  
 Takahashi, H., 302  
 Takahashi, N., 589  
 Takahashi, T., 151  
 Takahaski, H., 471  
 Takasugi, M., 413  
 Tamura, N., 67  
 Tan, C.-C., 503  
 Teehan, B. P., 548  
 Tepel, M., 775  
 Teraoka, S., 151  
 Testa, A., 486  
 Thiel, G., 242  
 Thoenes, G. H., 253  
 Tinawi, M., 648  
 Toma, H., 151  
 Tomita, J., 405  
 Torres, N., 340  
 Tretotola, S. O., 732  
 Tsukamoto, T., 637  
 Tsunoda, S., 67  
 Tuttle, A. B., 710  
 Vallino, F., 222  
 Vandenbroucke, J. P., 370  
 Van Saase, J. L. C. M., 370  
 Van Stone, J. C., 616  
 Vezzoli, G., 222  
 Wada, J., 680  
 Wagnild, J. P., 330  
 Waldherr, R., 336  
 Waltzer, W., 75  
 Watters, S. K., 603  
 Weber, J., 751  
 Wegmann, W., 242  
 Weinreich, T., 452  
 Wener, M. H., 330  
 Wetzels, J. F. M., 781  
 Whelton, P. K., 722  
 Whittier, F. C., 70  
 Widerøe, T.-E., 597  
 Wilkinson, A., 46, 629  
 Wingard, R. L., 433  
 Wolf, C. J., 343  
 Wolfe, R. A., 623  
 Wong, K. K. M., 810  
 Wu, Y.-Ching, 445  
 Wüthrich, R. P., 79  
 Yamabe, H., 67  
 Yamaguchi, T., 302, 471  
 Ye, M., 471  
 Yeun, J. Y., 297  
 Yokoyama, T., 492  
 Youn, S., 34  
 Yu, A. W., 810  
 Zhou, F. Q., 810  
 Zurovsky, Y., 46

## SUBJECT INDEX

Page references to supplement 1 (April 1995) are preceded by S1:

- Ab(s), *see* Antineutrophil cytoplasmic antibodies and entries beginning with term: Antibody
- Absorptive hypercalciuria, nonacidotic proximal tubulopathy with, 222-227
- Accelerated hypertension, hypertensive nephrosclerosis and, 215-216
- ACE inhibitors, *see* Angiotensin-converting enzyme inhibitor(s)
- Acetate dialysate in maintenance HD, effects of, on serum HDL-cholesterol concentrations, 584-588
- Acetate membranes, *see* Cellulose acetate membranes
- Acid dialysate, and metabolic alkalosis in CRF, 343-345
- Acquired immunodeficiency syndrome, *see* AIDS
- Acute cyclosporine A (CsA) nephrotoxicity in hypothyroidic renal transplantation recipient, 503-505
- Acute interstitial nephritis (AIN), ticlopidine-induced, 934-936
- Acute oliguric glomerulonephritis (GN), palpable purpura and, 651-659
- Acute postinfectious glomerulonephritis (GN), proteinase 3 and elastase distribution in, 253-261
- Acute rejection, late renal transplant, prognostic value of EPO serum levels in, 775-780
- Acute renal failure (ARF)
- allopurinol in prevention of renal hypouricemia and exercise-induced, 937-946
  - associated with IVIg therapy, 228-234
  - due to djenkolism, 63-66
  - effects of antioxidants on endotoxin-induced, 51-57
  - IgAN and, 340-342
  - with minimal change disease, 648-650
  - parenteral nutrition in, *see* Parenteral nutrition in ARF
  - severe, in AIDS, outcome of, 390-398
- Acute tubular necrosis (ATN), 648-659
- AIDS and, 390-398
- IgAN and, 340-342
  - minimal change disease presenting with, 648-650
  - oliguric, 651-659
- AD(s) (advance directives), influence of dialysis staff on patient's formulation of, 262-268
- Adenosine monophosphate, cyclic, cyst fluid in ADPKD stimulating accumulation of, 471-477
- Adenosine triphosphatase (ATPase),  $\text{Na}^+$ ,  $\text{K}^+$ , in hypertensive nephrosclerosis, racial variation in, 212
- Adenosine triphosphate (ATP) in diabetic CRF, effects of nifedipine on, 440-444
- ADPKD, *see* Autosomal dominant polycystic kidney disease
- Adult primary focal segmental glomerulosclerosis (FSGS), histology and prognosis of, 845-852
- Advance directives (ADs), influence of dialysis staff on patient's formulation of, 262-268
- Advanced chronic renal failure (CRF), hyperphosphatemia and secondary HPTH in, 665-666
- Advanced glycation end-products (AGEs), tissue and plasma, dialysis modality for ESRD and concentration of, 445-451
- African-Americans, *see* Race and ethnicity
- Agammaglobulinemia in renal transplantation with severe recurrent bacterial infections, 947-951
- Age
- of ARF patients, *see* Age of ARF patients
  - of CAVVH patients, 19
  - of chronic renal disease patients on rHEPO therapy, 550
  - of CRF patients, *see* Age of CRF patients
  - of familial ADPKD subjects, mortality and, 372
  - of idiopathic membranous glomerulopathy patients, 865
  - of MGN patients, 377
  - of MPGN patients with primary Sjögren's syndrome, 635
  - of outpatients undergoing renal biopsy, 877
  - of primary FSGS patients, 535-538
  - of *Pseudomonas* peritonitis patients, 771
  - of RRT patients, *see* Age of RRT patients
  - and TI lesions in young subjects, 478-488
  - of type II diabetes patients, 839
- Age of ARF patients, 64
- of exercise-induced ARF patients with renal hypouricemia, 942
  - of severe ARF with AIDS, 392, 393
- Age of CAPD patients
- and effects of pulse oral calcitriol, 292
  - and low-Ca dialysate, 454
  - and peritonitis, *see* Age of CAPD patients, peritonitis and with urologic cancers, 697
- Age of CAPD patients, peritonitis and polymicrobial peritonitis, 462
- and relapse into gram-positive peritonitis, 612
- Age of CRF patients
- with diabetic CRF, nifedipine effects on PMNL function and metabolism and, 441
  - of nondialyzed CRF patients, 889
  - see also* Age of ESRD patients
- Age of ESRD patients
- on HD, *see* Age of ESRD patients on HD
  - incidence of ESRD by diabetes, race and, 714-721
  - see also* Age of CRF patients
- Age of ESRD patients on HD
- of HIV-infected patients on maintenance HD, rHuEPO for, 906
  - on maintenance HD, 284, 285
  - pentosidine and, 446, 448
- Age of HD patients
- aminoguanidine pharmacokinetics and, 422
  - with atherosclerotic vascular diseases, 35
  - BP and prognosis of, 407
  - with chronic HCV and/or HBV infection on IFN- $\alpha$  therapy, 43
  - with diabetic CRF, nifedipine effects on PMNL function and metabolism and, 441
  - with ESRD, *see* Age of ESRD patients on HD
  - oxalosis and, 496
  - on rHEPO and Fe therapy, 434

- with uremic pruritus, 416
- with urologic cancers, 697
- Age of RRT patients
  - in Canada, 135, 142-143, 146, 148
  - and cardiac function in dialysis patients, S1:5
  - of chronic dialysis patients with HCV infection, 401
  - in France, 189-190
  - in Lombardy, 197, 201
  - in New Zealand and Australia, 172, 173
  - on PD, CABG and PTCA outcome and, 284
  - in U.S., 121, 128
  - see also* Age of CAPD patients; Age of HD patients; Age of transplant recipients
- Age of transplant recipients
  - allograft erythropoiesis and, 49
  - and lovastatin and nicotinic acid effects on hyperlipidemia and hypercholesterolemia, 617
  - outcome of transplantation in women of child-bearing age, 465-470
- AGEs (advanced glycation end-products), tissue and plasma, dialysis modality for ESRD and concentration of, 445-451
- AIDS (acquired immunodeficiency syndrome)
  - and disappearance of uremia due to HIVAN, 689-693
  - outcome of severe ARF in, 390-398
  - see also* HIV
- AIN (acute interstitial nephritis), ticlopidine-induced, 934-936
- Alanine aminotransferase in maintenance HD patients, 585
- Albumin
  - in HD patients with uremic pruritus, 416
  - in metabolic alkalosis, 344
  - plasma fluorescein binding by, in DM-associated ESRD, 543-547
  - in renal transplantation with severe bacterial infections, 948
  - serum, *see* Serum albumin
  - see also* Albuminuria
- Albuminuria
  - factors associated with, in type II diabetes, 836-844
  - see also* Microalbuminuria in DM; Proteinuria
- Aldosterone, plasma and serum, in hypokalemic hypertension, 830
- Alkaline phosphatase (ALP)
  - and hypervitaminosis A in HD patients, 347
  - and low-Ca dialysate in CAPD, 455-457
  - in nondialyzed CRF patients with secondary HPHT, 881
  - oxalosis of HD and, 496
- Alkalosis
  - metabolic, *see* Metabolic alkalosis
  - respiratory, in CAPD patients with pulmonary disease, 79-81
- Allograft(s), *see* Allograft survival; Rejection, renal transplant; Renal allografts
- Allograft survival
  - in Australia and New Zealand, 173-175
  - in Canada, 143-145, 148-150
  - donor type, race and, 623-628
  - in Japan, 159-162
  - in U.S., 129-130
- Allopurinol in prevention of renal hypouricemia and exercise-induced ARF, 937-946
- ALP, *see* Alkaline phosphatase
- Alpha ( $\alpha$ ) carotene in CRF and ESRD during HD, 566
- Alpha ( $\alpha$ )-linoleic acid in flax oil, effects of, in 5/6 nephrectomy, 320-329
- Alpha ( $\alpha$ ) tocopherol in CRF and ESRD during HD, 566
- Aluminum (Al)
  - and rHEPO and Fe therapy, 434
  - serum, *see* Serum aluminum
- Aluminum hydroxide, effects of, on PRF in hypertension, 910-917
- Ambulatory peritoneal dialysis, *see* Continuous ambulatory peritoneal dialysis
- Amiloride for hypokalemic hypertension of Liddle's syndrome, 829-825
- Amino acids in parenteral nutrition for ARF, 99
- Aminoguanidine, pharmacokinetics of, in ESRD patients on HD, 422-425
- Aminotransferase, alanine, in maintenance HD patients, 585
- Amplification complement (C3) convertase in MPGN type II, 853-861
- Amyloid P, and massive fibronectin deposits in familial GN, 781-791
- Amyloidosis in HD patients, 491-497
  - colonic dilatation due to, 807-809
- ANCAs, *see* Antineutrophil cytoplasmic antibodies
- Anemia of ESRD and/or CRF, *see* Recombinant human erythropoietin
- Aneurysms, dissection of spontaneous vertebral artery, ADPKD and, 70-74
- Angiodiagnosis of vascular access blood flow, 22-25
- Angiography, magnetic resonance, of RAS in PRF, 701-709
- Angioplasty, percutaneous transluminal coronary, outcome of CABG and, in maintenance HD and/or PD patients, compared, 281-290
- Angiotensin-converting enzyme (ACE) inhibitor(s)
  - enalapril in chronic renal disease with hypertension, effects of, on renal ET-1 production, 918-923
  - for microalbuminuria in DM, 111
  - renal dysfunction due to, in patients on long-term lithium therapy, 82-87
- Ankle-arm blood pressure (BP), as marker for atherosclerotic vascular diseases in HD patients, 34-39
- Antibody(ies) (Abs), HCV
  - in cryoglobulinemic GN, 365
  - transplant evaluation of ESRD patient positive for, 11-12
- Antibody(ies) (Abs) in GN
  - anti-glomerular basement membrane antibody with GN during pregnancy, effects of placenta on, 330-335
  - antineutrophil cytoplasmic antibodies, 253-261
  - HCV, in cryoglobulinemic GN, 365
- Antigen, HLA association with karyomegalic interstitial nephritis, 247-252
- Anti-glomerular basement membrane (anti-GBM) antibody, GN with, during pregnancy, effects of placenta on, 330-335
- Anti-HCV (hepatitis C virus)-positive end-stage renal disease (ESRD) patient, transplant evaluation of, 11-12
- Antihypertensive therapy, *see* Hypertension management
- Anti-inflammatory interleukins, biological control of TNF- $\alpha$  and IL-1 with, 961
- Antineutrophil cytoplasmic antibodies (ANCAs)



- in GN, 253-261  
in systemic vasculitis, relationship between disease activity and concentration of, 380-389
- Antioxidants**  
effects of, on endotoxin-induced ARF, 51-57  
estrogens as, and gender-related differences in chronic renal disease, 523  
and lipoprotein oxidation in CRF and during HD, 564-571
- Antiphospholipid syndrome (APS)**, primary, captopril and aspirin for renal microangiopathy in, 486-488
- APD** (automated peritoneal dialysis), optimization of dialysate flow and mass transfer during, 603-611
- Apolipoprotein A (apo A)** in CRF and ESRD during HD, 566
- Apolipoprotein B (apo B)** in CRF and ESRD during HD, 566
- Apolipoprotein E (apo E)** phenotype, lipoprotein glomerulopathy with new, 952-953
- APS** (antiphospholipid syndrome), primary, captopril and aspirin for renal microangiopathy in, 486-488
- ARF**, *see* Acute renal failure
- Arginine vasopressin (AVP)** gene expression in puromycin-induced NS, 58-62
- Arterial blood gases** in CAPD patient with respiratory alkalosis, 80
- Arterial pressure**, *see* Blood pressure
- Arteriovenous graft and fistula**, *see* Vascular access
- Ascorbic acid (vitamin C)** in CRF and ESRD during HD, 566
- Aspirin**, captopril and, for renal microangiopathy in primary APS, 486-488
- Associated disorders**  
with Bartter's syndrome, 819-820  
*see also specific conditions*
- Atherosclerosis**, and lipoprotein oxidation in CRF and during HD, 564-571
- Atherosclerotic vascular diseases** in HD patients, ankle-arm BP as marker for, 34-39
- ATN**, *see* Acute tubular necrosis
- ATP** (adenosine triphosphate) in diabetic CRF, effects of nifedipine on, 440-444
- ATPase** (adenosine triphosphatase),  $\text{Na}^+$ ,  $\text{K}^+$ , in hypertensive nephrosclerosis, racial variation in, 212
- Australia**, RRT in, 165-175
- Automated peritoneal dialysis (APD)**, optimization of dialysate flow and mass transfer during, 603-611
- Autonomous parathyroid cell proliferation** in secondary HPTH in CRF, 672
- Autosomal dominant polycystic kidney disease (ADPKD)**  
cyst fluid in, stimulating fluid secretion, cAMP accumulation, and Madin-Darby canine renal cell proliferation, 471-477  
familial, mortality in, 370-374  
prevention of progressive nephropathy in nondiabetic, 105  
spontaneous vertebral artery aneurysm dissection as complication of, 70-74
- AVP** (arginine vasopressin) gene expression in puromycin-induced NS, 58-62
- Bacteremia**, *E. coli*, tumefactive megalocytic interstitial nephritis with, 928-933
- Bacterial contamination** of HD water, 738-750
- Bacterial infections**  
severe recurrent, in renal transplantation, agammaglobulinemia in, 947-951  
*see also specific bacterial infections*
- Bartter's syndrome**, 813-822  
clinical features of, 814  
conclusion on, 820-821  
course and treatment of, 815-816  
diagnosis of, *see* Diagnosis, Bartter's syndrome  
disorders related to, 819-820  
Gitelman's syndrome and, *see* Gitelman's syndrome, as hypocalciuric variant of Bartter's syndrome  
pathophysiology of, 816-819
- Berger's disease**, *see* IgA nephropathy
- Beta ( $\beta$ ) carotene** in CRF and ESRD during HD, 566
- Beta<sub>2</sub>-microglobulin**, *see*  $\beta_2$ -Microglobulin
- BF**, *see* Blood flow
- Bicarbonate**, *see*  $\text{HCO}_3$
- Biochemistry**  
of TI lesions, 479  
*see also specific biochemical data*
- Bioincompatibility** of blood flow rates, and net generation of C3a in fast HD, 896-903
- Biological control** of TNF- $\alpha$  and IL-1, *see* Interleukin-1, biological control of; Tumor necrosis factor- $\alpha$ , biological control of
- Biology** of HCV, 3-4
- Biopsy**, *see* Renal biopsy
- Birth weight**, low, and racial differences in HTN, NIDDM, and ESRD, 350-356
- Blood flow (BF)**  
bioincompatibility of rates of, and net generation of C3a in fast HD, 896-903  
renal, in hypertensive nephrosclerosis, racial variations in, 212  
vascular access, angiodynography of, 22-25
- Blood gases**, arterial, in CAPD patient with respiratory alkalosis, 80
- Blood glucose**, lovastatin and nicotinic acid effects on, in renal transplantation, 617
- Blood pH** in Gitelman's syndrome, 826
- Blood pressure (BP)**  
of CAVVH patients, 19  
in Gitelman's syndrome, 826  
of HD patients, *see* Blood pressure of HD patients  
rhEPO effects on, S1:15-16  
*see also* Hypertension; Hypotension; Venous pressure
- Blood pressure (BP)** of HD patients  
ankle-arm, as marker for atherosclerotic vascular diseases, 34-39  
of CRF patients on HD, PRA and, 589-591  
prognosis and, 405-412
- Blood transfusions**  
in chronic renal disease patients, 550  
in ESRD patients, HCV infection and, 5-6  
in HCV-infected patients, 401, 402
- Blood urea nitrogen**, *see* BUN
- BMI**, *see* Body mass index
- Body mass index (BMI)**  
of nondialyzed CRF patients, 889  
in type II diabetes, 838-840

- Body weight (BW)  
 of CAVVH patients, 19  
 of familial hyperuricemic subjects, 237  
 of HD patients, *see* Body weight of HD patients  
 LBW hypothesis on racial differences in HTN, NIDDM, and ESRD, 350-356  
 of nephrectomized subjects, effects of flaxseed and flax oil diets and, 322, 323
- Body weight (BW) of HD patients  
 aminoguanidine pharmacokinetics and, 422
- BP, prognosis and, 407  
 of maintenance HD patients, 585  
 nutrition and interdialytic gain in, 579-583
- Bone disease, *see* Osteogenesis imperfecta; Renal osteodys-trophy in CAPD
- Bone dysplasia, and hereditary GS in conorenal syndrome, 792-798
- Bone mineral density, and low-Ca dialysate in CAPD, 457
- BP, *see* Blood pressure
- BUN (blood urea nitrogen)  
 in HD patients, *see* BUN in HD patients  
 in hypokalemic hypertension, 830  
 in nondialyzed CRF patients with secondary HPHT, 881  
 in puromycin-induced NS, 59
- BUN (blood urea nitrogen) in HD patients  
 predialysis BUN and IDWG, 580  
 with uremic pruritus, 416
- BW, *see* Body weight
- Bypass grafting, coronary artery, outcome of PTCA and, in maintenance HD and/or PD patients, compared, 281-290
- C3 (complement 3) in MPGN type II, paramesangial deposits correlated with levels of, 853-861
- C3a (complement 3a), net generation of, in fast HD, bioin-compatibility of blood flow rates and, 896-903
- Ca (calcium)  
 abnormal regulation of Ca-controlled PTH secretion in HPHT in CRF, 673-674  
 dialysate low in, *see* Low-calcium dialysate in CAPD  
 in HD patients with uremic pruritus, 416  
 in metabolic alkalosis, 344  
 plasma, *see* Plasma Ca  
 serum, *see* Serum Ca  
*see also*  $\text{Ca}^{2+}$ ;  $\text{Ca}_0^{2+}$ ;  $\text{CaC}_2\text{O}_4$ ; Hypercalcemia; Hypercalci-uria; Hypocalcemia *entries beginning with term: Hy-pocalcemic and element: Calc-*
- $\text{Ca}^{2+}$  (ionized calcium)  
 in CRF, *see*  $\text{Ca}^{2+}$  in CRF  
 and SIPA in uremic patients on HD, 558, 559
- $\text{Ca}^{2+}$  (ionized calcium) in CRF  
 in diabetic CRF, effects of nifedipine on, 440-444  
 in nondialyzed CRF patients with secondary HPHT, 881
- $\text{Ca}_0^{2+}$  (ionized Ca concentration), sensing of extracellular, by parathyroid and renal cells, 506-513
- CABG (coronary artery bypass grafting), outcome of PTCA and, in maintenance HD and/or PD patients, com-pared, 281-290
- $\text{CaCO}_3$  (calcium carbonate)  
 oral, effects of, on progressive renal failure in hyperten-sion, 910-917  
 for secondary HPHT in nondialyzed CRF patients, 879-886  
 $\text{CaC}_2\text{O}_4$  (calcium oxalate), deposition of cutaneous, in HD patient, 492-497
- Cadaveric donors (CAD), allograft survival with  
 race and, 623-628  
 transplant patient survival and, in Canada, 143, 147, 149-150
- Calcemic response in secondary HPHT in CRF, 666-668
- Calciphylaxis presenting with calf pain in CAPD and predial-ysis patients, 498-502
- Calcitriol, *see* 1,25-Dihydroxyvitamin  $\text{D}_3$
- Calcium, *see* Ca
- Calcium carbonate, *see*  $\text{CaCO}_3$
- Calcium oxalate ( $\text{CaC}_2\text{O}_4$ ), deposition of cutaneous, in HD patients, 492-497
- Calculi, renal, in nonacidotic proximal tubulopathy with ab-sorptive hypercalciuria, 222-227
- Calf pain, calciphylaxis presenting with, in CAPD and predi-alysis patients, 498-502
- cAMP (cyclic adenosine monophosphate), cyst fluid in ADPKD stimulating accumulation of, 471-477
- Canada, RRT in, 134-150
- Cancers  
 in Canadian patients, RRT patient survival compared with survival of, 140-141  
 urologic, in uremia, 694-700
- CAPD, *see* Continuous ambulatory peritoneal dialysis
- Captopril, aspirin and, for renal microangiopathy in primary APS, 486-488
- Carbohydrates in IVIg preparations, ARF and, 228-234
- Carbon dioxide, *see* Total  $\text{CO}_2$
- Cardiac function, effects of higher HCT levels on, in dialysis patients, S1:3-7
- Cardiovascular risk factors  
 and HCT levels in dialysis patients, S1:3-7  
 renal-, relationship between microalbuminuria in DM and, 109-110
- Care staff, *see* Dialysis staff
- $\alpha$  (alpha) and  $\beta$  (beta) Carotene in CRF and ESRD during HD, 566
- Carpal tunnel syndrome, and HD-related amyloidosis, 807-809
- Catabolic rate, *see* Protein catabolic rate in HD patients
- Catecholamines  
 plasma and serum, and urinary excretion of, in hypoka-lemic hypertension, 830  
 racial variation in, hypertensive nephrosclerosis and, 212  
*see also specific catecholamines*
- Catheters, *see* Double-lumen catheters; Silicone catheters;  
 Vascular access
- CAVVHD (continuous venovenous hemodiafiltration) in in-fants and children, 17-21
- CCPD (continuous cycling peritoneal dialysis), trough serum vancomycin levels and gram-positive peritonitis re-lapse in, 611-615
- Cell proliferation  
 autonomous parathyroid, in secondary HPHT in CRF, 672  
 renal epithelial, cyst fluid in ADPKD stimulating, 471-477
- Cellular effects of TNF- $\alpha$ , 955
- Cellulose acetate membranes



- lipoprotein oxidation with, 566, 567
  - for plasma porphyrin removal in ESRD, 30-33
- Chemical contamination of HD water, 738-750
- Chest x-ray of PD patients with pneumoperitoneum, 297-301
- Child-bearing age, outcome of renal transplantation in women of, 465-470
- Children
- CAVVHD in, 17-21
  - neonatal severe hyperparathyroidism, extracellular  $\text{Ca}^{2+}$ -sensing receptor in, 506-513
- Chloride, *see* Cl and  $\text{Cl}^-$
- Cholesterol
  - in CRF and ESRD during HD, 566
  - HDL-, *see* High-density lipoprotein-cholesterol
  - lovastatin and nicotinic acid effects on hypercholesterolemia in renal transplantation, 616-622
  - plasma, effects of flaxseed and flax oil diets on, in 5/6 nephrectomy, 323, 324
  - total, *see* Total cholesterol
- Chromosome 16 in familial ADPKD, 370-374
- Chronic dialysis
  - HCV infection in patients on, 399-404
  - see also* Maintenance hemodialysis
- Chronic hepatitis, and HCV infection in HD patients, 572-578
- Chronic hepatitis B virus (and/or hepatitis C virus) infection in HD patients, IFN- $\alpha$  facilitating renal transplantation in, 40-45
- Chronic intermittent hemodialysis (HD), Pcr determination in patients on, 887-895
- Chronic renal disease
  - with hypertension, reduced renal mass and renal ET-1 production in, 918-923
  - predialysis, HRQL associated with rhEPO in, 543-554
  - see also* Chronic renal disease progression and specific conditions
- Chronic renal disease progression
  - gender and, *see* Chronic renal disease progression, gender-related differences in
  - preventing, 103-106
- Chronic renal disease progression, gender-related differences in, 515-533
  - animal models of renal injury and, 517-518
  - clinical studies of, 516-517
  - diet and, 521
  - and disease prevalence, 515-516
  - glomerular number and size and, 518-519
  - growth factors and cytokines and, 521, 523
  - hypertension and, 520-521
  - and kidney size, 518
  - prostaglandins and, 522-523
  - renal hemodynamics and, 519-520
  - renin-angiotensin system and, 522
  - sex hormones and, *see* Sex hormones, and gender-related differences in chronic renal disease progression
- Chronic renal failure (CRF)
  - anemia of, *see* Recombinant human erythropoietin
  - lipoprotein oxidation in, 564-571
  - with osteogenesis imperfecta, 489-491
  - secondary HPHT in, *see* Chronic renal failure, secondary HPHT and
- see also* End-stage renal disease; Hemodialysis for CRF; Nondialyzed chronic renal failure patients; Uremia
- Chronic renal failure (CRF), secondary HPHT and  $\text{CaCO}_3$  for, in nondialyzed patients, 879-886
  - see also* Chronic renal failure, trade-off hypothesis of secondary HPHT in
- Chronic renal failure (CRF), trade-off hypothesis of secondary HPHT in, 663-679
  - abnormal regulation of Ca-controlled PTH secretion in, 673-674
  - altered PTH degradation in, 672-673
  - altered vitamin D metabolism and resistance to calcitriol in, 668-672
  - autonomous parathyroid cell proliferation in, 672
  - hyperphosphatemia and, 664-666
  - hypocalcemia and, 664
  - impaired calcemic response in, 666-668
- Cigarette smoking, *see* Smoking
- Cl and  $\text{Cl}^-$  (chloride)
  - in metabolic alkalosis, 344
  - plasma, *see* Plasma Cl
  - serum, *see* Serum Cl
- Classification
  - of crescentic GN, 652
- ESRD, epidemiologic study and, 725-727, 729
- Clinical course, *see* Course
- Clinical features and presentation
  - of Bartter's syndrome, 814
  - of calciphylaxis with calf pain in CAPD and predialysis patients, 498-502
  - of cryoglobulinemic GN, 363
  - of FSGS, 534-542
  - of HD oxalosis, 496
  - of idiopathic membranous glomerulopathy, 868
  - intrinsic renal diseases mimicking hypertensive nephrosclerosis, 214-215
  - of MGN, 377
  - of minimal change disease with ATN, 648-650
- Clotting, vascular access, by heparin in ESRD patient, 642-647
- $\text{CO}_2$  (carbon dioxide), *see* Total  $\text{CO}_2$
- Collagen, type IV, distribution of, in GN, 680-688
- Colonic dilatation due to HD-related amyloidosis, 807-809
- Common variable immunodeficiency (CVID) in renal transplantation with severe recurrent bacterial infections, 947-951
- Complement 3 (C3) in MPGN type II, paramesangial deposits correlated with levels of, 853-861
- Complement 3a (C3a), net generation of, in fast HD, biocompatibility of blood flow rates and, 896-903
- Complete remission in idiopathic membranous glomerulopathy, therapy and, 871
- Compliance with rhEPO and Fe therapy, 437
- Complications, *see* Nephrotoxicity; Side effects *specific conditions and therapeutic modalities*
- Composition of paramesangial glomerular deposits in MPGN type II, 856-858
- Concurrent hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in ESRD patients, 7

- in renal transplantation recipients, 10
- Cone-shaped epiphyses of phalanges in conorenal syndrome, 792-798
- Congenital alterations, renal and pancreatic, and low birth weight, 351-352
- Conjugated dienes, and lipoprotein oxidation in CRF and during HD, 564-571
- Connective tissue disease, and spontaneous vertebral artery aneurysm dissection with ADPKD, 70-74
- Conorenal syndrome, hereditary GS in, 792-798
- Continuous ambulatory peritoneal dialysis (CAPD)
  - calciophylaxis presenting with calf pain in, 498-502
  - dialysate in, *see* Continuous ambulatory peritoneal dialysis, dialysate in
  - for ESRD, *see* Continuous ambulatory peritoneal dialysis for ESRD
  - peritonitis in, *see* Peritonitis in CAPD
  - pulmonary disease in patients on, respiratory alkalosis and, 79-81
  - pulse oral calcitriol in patients on, 291-296
  - with severe LVSD, 761-768
  - see also* Renal replacement therapy registry(ies)
- Continuous ambulatory peritoneal dialysis (CAPD), dialysate in
  - optimization of dialysate flow and mass transfer during CAPD, 603-611
  - see also* Low-calcium dialysate in CAPD
- Continuous ambulatory peritoneal dialysis (CAPD) for ESRD
  - HCV infection and, 5
  - urologic cancers in patients on, 694-700
- Continuous cycling peritoneal dialysis (CCPD), trough serum vancomycin levels and gram-positive peritonitis relapse in, 611-615
- Continuous venovenous hemodiafiltration (CAVVHD) in infants and children, 17-21
- Convertase, amplification C3, in MPGN type II, 853-861
- Coronary angioplasty, percutaneous transluminal, outcome of CABG and, in maintenance HD and/or PD patients, compared, 281-290
- Coronary artery bypass grafting (CABG), outcome of PTCA and, in maintenance HD and/or PD patients, compared, 281-290
- Corticosteroids
  - for idiopathic membranous glomerulopathy, review of, 862-875
  - see also* specific corticosteroids
- Cortisol, serum and plasma, in hypokalemic hypertension, 830
- Cost
  - and benefits of microalbuminuria management in DM patients, 112
  - of MRA, 706
  - of RRT in U.S., 125
- Course
  - of Bartter's syndrome, 815-816
  - of primary FSGS, 543-542
  - see also* Progression and specific conditions
- Creatinine (Cr; CRE) and creatinine (Cr; CRE) clearance
  - effects of antioxidants on, in endotoxin-induced ARF, 55
  - in familial hyperuricemia, 237
  - in HD patients with uremic pruritus, 416
  - hypercreatinemia in essential hypertension, 213
  - mass transfer area coefficient for, during APD, 605
  - in nondialyzed CRF patients with secondary HPHT, 881
  - of MPGN patients with primary Sjögren's syndrome, 635
  - plasma, *see* Plasma creatinine
  - in primary FSGS, 535-539
  - serum, *see* Serum creatinine
- Crescentic glomerulonephritis (GN), 651-659
  - see also* specific conditions
- CRF, *see* Chronic renal failure
- Cryoglobulinemia
  - essential mixed, HCV infection in, 12-13
  - see also* Cryoglobulinemic glomerulonephritis, HCV infection and
- Cryoglobulinemic glomerulonephritis (GN), HCV infection and
  - cyclophosphamide for, 798-800
  - and HCV-induced cryoglobulinemic GN, 361-369
- Crystalline deposition disease, recurrent IgA- $\kappa$ , after renal transplantation, 75-78
- CsA (cyclosporine A) nephrotoxicity, acute, in hypothyroidic renal transplantation recipient, 503-505
- Cuprophane membranes
  - lipoprotein oxidation with, 568
  - for plasma porphyrin removal in ESRD, 30-33
- Cutaneous  $\text{CaC}_2\text{O}_4$  (calcium oxalate), deposition of, in HD patient, 492-497
- CVID (common variable immunodeficiency) in renal transplantation with severe recurrent bacterial infections, 947-951
- CyA (cyclosporine A) nephrotoxicity, acute, in hypothyroidic renal transplantation recipient, 503-505
- Cyclic adenosine monophosphate (cAMP), cyst fluid in ADPKD stimulating accumulation of, 471-477
- Cycling peritoneal dialysis, continuous, trough serum vancomycin levels and gram-positive peritonitis relapse in, 611-615
- Cyclophosphamide
  - for GN, *see* Cyclophosphamide for GN
  - for idiopathic membranous glomerulopathy, review of, 862-875
- Cyclophosphamide for GN
  - for cryoglobulinemic GN associated with HCV infection, 798-800
  - for palpable purpura and acute oliguric GN, 652-659
- Cyclosporine A (CsA; CyA) nephrotoxicity, acute, in hypothyroidic renal transplantation recipient, 503-505
- Cyst fluid in ADPKD stimulating fluid secretion, cAMP accumulation, and Madin-Darby canine renal cell proliferation, 471-477
- Cytochrome P-450, and acute CsA nephrotoxicity in hypothyroidic renal transplantation recipient, 503-505
- Cytokines
  - and gender-related differences in chronic renal disease progression, 521, 523
  - see also* Interleukin-1, biological control of; Tumor necrosis factor- $\alpha$ , biological control of
- Cytoplasmic antibodies, *see* Antineutrophil cytoplasmic antibodies
- Cytosolic calcium, *see*  $\text{Ca}^{2+}$ ;  $\text{Ca}_i^{2+}$

- D (dopamine), serum and plasma, in hypokalemic hypertension, 830
- Data and database  
of Japanese RRT registry, 151-152  
of New Zealand and Australian registries, 165-166  
USRDS, 120-124
- DBP (diastolic blood pressure), *see* Blood pressure
- Death  
discussions on ADs with dialysis staff and attitudes toward, 261-268  
in first 90 days of dialysis, 277  
uncertain cause of ESRD, epidemiologic study and, 725  
*see also* Mortality
- Demographic characteristics, *see* Patient characteristics
- Deoxyribonucleic acid (DNA) detection, HCV, 4, 5
- Diabetes mellitus (DM)  
incidence of ESRD by age, race and, 714-721  
*see also* Microalbuminuria in DM; Non-insulin-dependent diabetes mellitus and *entries beginning with term*: Diabetic
- Diabetic end-stage renal disease (ESRD)  
HD for, pharmacokinetics of aminoguanidine in, 420-425  
influence of dialysis modality on plasma and tissue pentosidine concentrations, 445-451  
NIDDM and, *see* Non-insulin-dependent diabetes mellitus, ESRD and  
plasma fluorescein binding by albumin and TCFER in, 543-547
- Diabetic nephropathy  
and cardiac function in dialysis patients, S1:5  
in HD patients, *see* Diabetic nephropathy in HD patients  
and peritonitis in PD patients, 612, 771  
prevention of progressive nephropathy in, 103-104  
*see also* Diabetic end-stage renal disease
- Diabetic nephropathy in HD patients  
and atherosclerotic vascular diseases, 35  
with diabetic CRF, nifedipine effects on PMNL function and metabolism in, 440-444  
pharmacokinetics of aminoguanidine and, 420-425  
prognosis and, 407  
with uremic pruritus, 416
- Diagnosis and detection  
of Bartter's syndrome, *see* Diagnosis, Bartter's syndrome of cryoglobulinemic GN, 363  
differential, *see* Differential diagnosis  
HCV infection, *see* Diagnosis and detection, HCV infection  
of microalbuminuria in DM, 110-111  
of vasculitis, 381  
*see also specific diagnostic techniques and specific conditions*
- Diagnosis, Bartter's syndrome, 814-815  
differential, between Gitelman's and Bartter's syndrome, 637-641
- Diagnosis and detection, HCV infection  
HCV DNA, 4, 5  
HCV RNA, 9-10, 572-578  
immunodiagnosis, *see* Immunodiagnosis of HCV infection  
serologic, 4-5, 9
- Dialysate  
in CAPD, *see* Continuous ambulatory peritoneal dialysis, dialysate in  
in maintenance HD, *see* Maintenance hemodialysis, dialysate in  
optimization of flow and mass transfer of, during APD, 603-611  
total spent, collection of representative fraction of, 810-812
- Dialysis  
for severe ARF in AIDS patients, 394  
*see also* Dialysis centers and units; Dialysis efficacy; Dialysis for ESRD; Dialysis membranes; Dialysis modality(ies); Dialysis staff; Higher hematocrit levels for dialysis patients; Renal replacement therapy registry (ies); Time on dialysis
- Dialysis centers and units  
adapting, to higher HCT levels in patients, S1:12-17  
effects of size of, on Canadian renal transplant recipients' survival, 146, 147, 149  
European, 176, 177  
Japanese, 153  
U.S., 125
- Dialysis efficacy  
for ESRD, plasma and tissue pentosidine concentrations and, 445-451  
of HD, and improvement of uremic pruritus, 413-419  
and urea rebound, 26-29  
*see also* Kt/V urea
- Dialysis fistula, *see* Vascular access
- Dialysis for ESRD  
death during first 90 days of, 276-280  
dialysis modality and plasma and tissue concentration of AGEs, 445-451  
*see also* Continuous ambulatory peritoneal dialysis for ESRD; End-stage renal disease, HCV infection in; Hemodialysis for ESRD
- Dialysis membranes  
effects of different, on SIPA in uremia, 558, 560  
in fast HD, C3a generation and, 896-903  
high permeability, for plasma porphyrin removal in ESRD, 30-33  
*see also specific types of membranes; for example*: Cellulose acetate membranes
- Dialysis modality(ies)  
in Canada, 144-145  
in France, 190  
in Lombardy, 197  
tissue and plasma concentrations of AGEs and, 445-451  
in U.S., 124, 125, 128  
*see also* Chronic dialysis; Continuous ambulatory peritoneal dialysis; Continuous cycling peritoneal dialysis; Hemodialysis; Peritoneal dialysis
- Dialysis staff  
HCV infection among, 6  
influence of, on patient's formulation of ADs, 262-268
- Dialyzer reuse  
in Canada, 137  
in U.S., 125
- Diastolic blood pressure, *see* Blood pressure
- Dienes, conjugated, and lipoprotein oxidation in CRF and during HD, 564-571
- Diet  
and dietary protein intake of nondialyzed CRF patients, urea output and urea generation rate and, 887-895

- flaxseed and flax oil, effects of, in 5/6 nephrectomy, 320-329
- and gender-related differences in chronic renal disease progression, 521
- of maintenance HD patients, 585
- see also* Nutrition
- Differential diagnosis
- of Bartter's and Gitelman's syndromes, 637-641
- of RPGN, 651-659
- 1,25-Dihydroxyvitamin D<sub>3</sub> [calcitriol; 1,25(OH)<sub>2</sub>D<sub>3</sub>; 1,25-dihydroxycholecalciferol]
- in nondialyzed CRF patients with secondary HPHT, 881
- in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 224
- pulse oral, limitations of, in CAPD patients, 291-296
- resistance to, in secondary HPTH in CRF, 668-672
- Dilatation, colonic, due to HD-related amyloidosis, 807-809
- Dimethylthiourea (DMTU), effects of, on endotoxin-induced ARF, 51-57
- Dismutase, superoxide, effects of, on endotoxin-induced ARF, 51-57
- Dissection, spontaneous vertebral artery aneurysm, as complication of ADPKD, 70-74
- Djenkolism, ARF due to, 63-66
- DM, *see* Diabetes mellitus
- DMTU (dimethylthiourea), effects of, on endotoxin-induced ARF, 51-57
- DNA (deoxyribonucleic acid) detection, HCV, 4, 5
- Donors, *see* Cadaveric donors, allograft survival with; Living-related donors, allograft survival with; Renal transplantation
- Dopamine (D), serum and plasma, in hypokalemic hypertension, 830
- Dose, rhEPO, hematocrit and, 437
- Double-lumen catheters
- IVUS imaging of malfunction of, and of thrombus formation on, 597-602
- percutaneous translumbar IVC cannulation with silicone, in HD, 732-737
- Drug interaction, lithium-ACE inhibitor, renal dysfunction and, 82-87
- Duration of dialysis, *see* Time on dialysis
- Dysostosis, and hereditary GS in conorenal syndrome, 792-798
- Dysplasia
- bone, and hereditary GS in conorenal syndrome, 792-798
- unilateral renal, NS and, 88-95
- E (epinephrine), serum and plasma, in hypokalemic hypertension, 830
- E coli* (*Escherichia coli*) bacteremia, tumefactive megalocytic interstitial nephritis with, 928-933
- Early chronic renal failure (CRF), hyperphosphatemia and secondary HPTH in, 664-665
- Early renal insufficiency, markers for, and epidemiologic study of kidney disease, 724
- ECM (extracellular matrix) receptors, distribution of, in GN, 680-688
- EDTA-ERA (European Dialysis and Transplantation Association-European Renal Association) Registry, 176-187
- Education, and completion of ADs by dialysis patients, 263
- Elastase, distribution of, in GN, 253-261
- ELISA (enzyme-linked immunosorbent assay) of systemic vasculitis, 380-389
- EMC (essential mixed cryoglobulinemia), HCV infection in, 12-13
- EME (extramedullary erythropoiesis), intrarenal, in renal allograft fine-needle aspirates, 46-50
- Enalapril in chronic renal disease with hypertension, effects of, on renal ET-1 production, 918-923
- Endothelin-1 (ET-1), renal, reduced renal mass and production of, in chronic renal disease with hypertension, 918-923
- Endotoxin
- effects of antioxidants on ARF induced by, 51-57
- in HD water, 738-750
- End-stage renal disease (ESRD)
- anemia in, *see* Recombinant human erythropoietin
- diabetic, *see* Diabetic end-stage renal disease
- HCV infection in, *see* End-stage renal disease, HCV infection in
- hypertensive nephrosclerosis and, *see* Hypertensive nephrosclerosis
- race and, *see* Race and ethnicity, ESRD and
- rhHuEPO for HIV-infected ESRD patients, 904-909
- RRT of, *see* Continuous ambulatory peritoneal dialysis for ESRD; Dialysis for ESRD; Hemodialysis for ESRD; Renal replacement therapy registry(ies); Renal transplantation
- see also* Chronic renal failure; Epidemiologic study of ESRD
- End-stage renal disease (ESRD), HCV infection in, 4-8
- concurrent HBV and HCV infection in, 7
- duration of dialysis and, 6
- molecular detection of HCV infection in, 4-5
- serologic detection of infection, 4-5, 9
- serum transaminases as marker of HCV infection and, 6
- transmission of, *see* Transmission of HCV infection to ESRD patients
- and transplant evaluation of anti-HCV-positive patient, 11-12
- treatment of, 8; *see also* Interferon- $\alpha$  for HCV infection
- Enzyme-linked immunosorbent assay (ELISA) of systemic vasculitis, 380-389
- Epidemiologic study of ESRD, 722-731
- as lagging discipline, 723
- methodologic obstacles to, 724-727
- policy-related obstacles to, 723-724
- prevention and, 728-730
- proposed solutions to, 727-728
- Epinephrine (E), serum and plasma, in hypokalemic hypertension, 830
- Epiphyses, cone-shaped phalange, in conorenal syndrome, 792-798
- Epithelial cell proliferation, renal, cyst fluid in ADPKD stimulating, 471-477
- Epoetin (EPO), *see* Erythropoietin
- Erythropoiesis, intrarenal extramedullary, in renal allograft fine-needle aspirates, 46-50
- Erythropoietin (EPO; epoetin)
- prognostic value of serum levels of, in late acute rejection of renal transplantation, 775-780

- see also Recombinant human erythropoietin  
*Escherichia coli* (*E. coli*) bacteremia, tumefactive megalocytic interstitial nephritis with, 928-933  
 ESRD, *see* End-stage renal disease  
 Essential hypertension  
   heterogeneous nature of, 211-213  
   hypercreatinemia in, 213  
 Essential mixed cryoglobulinemia (EMC), HCV infection in, 12-13  
 Estrogen, role of, and gender-related differences in chronic renal disease, 523-524  
 ET-1 (endothelin-1), renal, reduced renal mass and production of, in chronic renal disease with hypertension, 918-923  
 Ethnicity, *see* Race and ethnicity  
 Etiology  
   of ARF in AIDS patients, 392-394  
   of Bartter's syndrome, 814  
   of pneumoperitoneum in PD patients, 298  
   *see also* Epidemiologic study of ESRD and specific conditions  
 European Dialysis and Transplantation Association-European Renal Association (EDTA-ERA) Registry, 176-187  
 Exercise-induced acute renal failure (ARF), allopurinol in prevention of renal hypouricemia and, 937-946  
 Extracellular  $\text{Ca}^{2+}$  (ionized Ca concentration), sensing of, by parathyroid and renal cells, 506-513  
 Extracellular matrix (ECM) receptors, distribution of, in GN, 680-688  
 Extramedullary erythropoiesis (EME), intrarenal, in renal allograft fine-needle aspirates, 46-50  
 Factor H in MPGN type II, 853-861  
 Familial autosomal polycystic kidney disease (ADPKD), mortality in, 370-274  
 Familial glomerulonephritis (GN), massive fibronectin deposits in, 781-791  
 Familial hyperuricemia with precocious gout and hypertension, 235-241  
 Familial hypocalciuric hypercalcemia, extracellular  $\text{Ca}^{2+}$ -sensing receptor in, 506-513  
 Familial predisposition  
   to ESRD in African-Americans with NIDDM, 710-713  
   to hypertensive nephrosclerosis, 218  
   to nonacidotic proximal tubulopathy with absorptive hypercalciuria, 224-225  
 Fast hemodialysis (HD), bioincompatibility of blood flow rates and net generation of C3a in, 896-903  
 Fasting glucose in type II diabetes, 838  
 Fe (iron)  
   in familial hyperuricemia, 237  
   serum, in HIV-infected patients on maintenance HD, 906  
   urinary, speciation of, in NS, 314-319  
   *see also* Fe therapy  
 Fe (iron) therapy, 426-439  
   in HD, zinc protoporphyrin and need for, 426-432  
   oral, with rhEPO, 433-439  
 Ferritin  
   in HIV-infected patients on maintenance HD, 906  
   *see also* Ferritin, Fe therapy and  
   Ferritin, Fe therapy and  
     and oral Fe therapy with rhEPO, 433-439  
     zinc protoporphyrin and, in HD, 428-430  
 Fibrillary glomerulonephritis (GN), fibronectin in, 781-791  
 Fibronectin in GN  
   distribution of, 680-688  
   massive fibronectin deposits in familial GN, 781-791  
 Fine-needle aspirates of renal allografts, intrarenal EME of, 46-50  
 Fistula, arteriovenous, *see* Vascular access  
   5/6 nephrectomy, effects of flaxseed and flax oil diets in, 320-329  
 Flaxseed (and flax oil) diet, effects of, in 5/6 nephrectomy, 320-329  
 Fluid, cyst, in ADPKD stimulating fluid secretion, cAMP accumulation, and Madin-Darby canine renal cell proliferation, 471-477; *see also* Autosomal dominant polycystic kidney disease  
 Fluorescein, binding of, by albumin, and TCFER in DM-associated ESRD, 543-547  
 Foam cells in primary FSGS, prognosis and, 854-852  
 Focal segmental glomerulosclerosis (FSGS)  
   primary, *see* Primary focal segmental glomerulosclerosis  
   unilateral renal dysplasia and, 88-95  
 Forskolin, effects of cyst fluid in ADPKD on, 473, 475  
 Fractional excretion  
   K, Cl, and Na, in Gitelman's syndrome, 826  
   *see also* Fractional urate excretion  
 Fractional urate excretion  
   in familial hyperuricemia, 235-241  
   in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 223  
 France, RRT in, 188-195  
 Free porphyrins, high permeability membranes for removal of, in ESRD, 30-33  
 FSGS, *see* Focal segmental glomerulosclerosis  
 Functional status of ESRD patients with severe LVSD on CAPD, 764  
 Funding, 122-125  
   of RRT in U.S., 124-125  
   of USRDS database, 122-123  
 Furosemide in Bartter's and Gitelman's syndromes, 637-641  
 Gamma ( $\gamma$ ) tocopherol in CRF and ESRD during HD, 566  
 Gender, *see* Sex  
 Gene expression, AVP, in puromycin-induced NS, 58-62  
 General health care system, U.S., reimbursement in, 124  
 General population, Canadian, RRT patient survival compared with cancer patients and, 140-141  
 Genetics  
   of hypertensive nephrosclerosis, *see* Hypertensive nephrosclerosis  
   of karyomegalic interstitial nephritis, 242-252  
   of nonacidotic proximal tubulopathy with absorptive hypercalciuria, 224-225  
   *see also* DNA; Gene expression; RNA and entries beginning with terms: Autosomal, Familial, Hereditary  
 Geographic structures, Canadian, RRT and, 134  
 GF(s) (growth factors), and gender-related differences in chronic renal disease progression, 521, 523  
 GFR, *see* Glomerular filtration rate  
 Gitelman's syndrome, as hypocalciuric variant of Bartter's syndrome



- normal prostaglandinuria  $E_2$ , 824-828
- renal clearance study in differentiating between Bartter's syndrome and, 637-641
- Globulin in renal transplantation with severe recurrent bacterial infections, 948
- Glomerular deposits, paramesangial, in MPGN type II correlated with hypocomplementemia, 853-861
- Glomerular filtration rate (GFR)
- of chronic renal disease patients on rhEPO therapy, 550
  - effects of antioxidants on, in endotoxin-induced ARF, 55
  - flaxseed and flax oil diet effects on, in 5/6 nephrectomy, 324
  - in hypertension, effects of oral  $CaCO_3$  on, 914
  - of type II diabetes patients, 840
- Glomerular injury
- and 5/6 nephrectomy, effects of flaxseed and flax oil diets on, 320-329
  - see also specific conditions*
- Glomerular number and size, and gender-related differences in chronic renal disease progression, 518-519
- Glomerulomegaly, NS and, 88-95
- Glomerulonephritis (GN)
- acute oliguric, palpable purpura and, 651-659
  - acute postinfectious, HUS complicating, 336-339
  - antibodies in, *see* Antibody(ies) in GN
  - distribution of proteinase 3 and elastase in, 253-261
  - ECM receptor distribution in, 680-688
  - fibronectin in, *see* Fibronectin in GN
  - HCV infection in, 12; *see also* Membranoproliferative glomerulonephritis, HCV infection in
  - membranoproliferative, *see* Membranoproliferative glomerulonephritis; Membranoproliferative glomerulonephritis type II
  - membranous, tubulointerstitial lesions in, proteinuria and, 375-379
  - rapidly progressive, *see* Rapidly progressive glomerulonephritis
  - TNF- $\alpha$  and IL-1 in, *see* Interleukin-1, biological control of; Tumor necrosis factor- $\alpha$ , biological control of
- Glomerulosclerosis (GS)
- hereditary, in conorenal syndrome, 792-798
  - in hypertension, oral  $CaCO_3$  effects on, 910-917
  - see also* Focal segmental glomerulosclerosis
- Glucose
- blood, lovastatin and nicotinic acid effects on, in renal transplantation, 617
  - fasting, in type II diabetes, 838
  - mass transfer area coefficient for, during APD, 605
  - and nifedipine effects on PMNL metabolism and function in diabetic CRF, 441
- Glucosuria in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 223
- Glycation end-products, advanced tissue and plasma, dialysis modality for ESRD and concentration of, 445-451
- Glycemic control in microalbuminuria, 111
- Glycoprotein (GP), platelet membrane, and effects of HD on SIPA in uremia, 555-563
- Glycosylated Hb (hemoglobin) in type II diabetes, 838, 839
- GN, *see* Glomerulonephritis
- Gout, precocious, familial hyperuricemia with hypertension and, 235-241
- GP (glycoprotein), platelet membrane, and effects of HD on SIPA in uremia, 555-563
- Grafts, *see* Renal allografts; Renal transplantation; Vascular access
- Gram-positive peritonitis, trough serum vancomycin levels and relapse of, in CAPD and CCPD patients, 611-615
- Granulocyte serine proteinases, distribution of proteinase 3 and elastase, in GN, 253-261
- Granulomatosis, Wegener's, proteinase 3 and elastase distribution in, 253-261
- Growth factors (GFs), and gender-related differences in chronic renal disease progression, 521, 523
- GS, *see* Glomerulosclerosis
- Guidewire exchange in management of long-term tunnelled silicone catheter-related sepsis, 593-596
- $H_2O_2$  (superoxide) production by peritoneal macrophages in CAPD, low-Ca dialysate and, 754, 755
- HAN (heroin-associated nephropathy), disappearance of uremia due to, 689-693
- Hand skeletal radiography, and low-Ca dialysate in CAPD, 457
- Hb (hemoglobin)
- and cardiac function in dialysis patients, S1:5
  - glycosylated, in type II diabetes, 838, 839
  - in HD patients with uremic pruritus, 416
  - and late acute rejection of renal transplant, 776
- HBV infection, *see* Hepatitis B virus infection
- $HCO_3^-$  (bicarbonate)
- effects of  $HCO_3^-$  dialysate on serum HDL-cholesterol concentrations in maintenance HD, 584-588
  - in metabolic alkalosis, 344
  - plasma, *see* Plasma  $HCO_3^-$
  - serum, and death during first 90 days of dialysis for ESRD, 278
- HCT, *see* Hematocrit
- HD, *see* Hemodialysis
- HDLs, *see* High-density lipoprotein(s); High-density lipoprotein-cholesterol
- Health care system
- in Australia, 166-167
  - in Canada, 134-135
  - in New Zealand, 167
  - U.S. general, 126
- Health-related quality of life (HRQL) associated with rhEPO in predialysis chronic renal disease patients, 543-554
- Heart disease, ischemic, in dialysis patients, S1:5
- Heart rate in Gitelman's syndrome, 826
- Height of HD patients
- aminoguanidine pharmacokinetics and, 422
  - BP and prognosis of, 407
- Hematocrit (HCT)
- in diabetic CRF, nifedipine effects on PMNL metabolism and function and, 441
  - of HIV-infected patients on maintenance HD, 906, 907
  - of nondialyzed CRF patients, 889
  - of predialysis chronic renal disease patients on rhEPO therapy, 550, 552
  - and rhEPO and Fe therapy, 436, 437
  - see also* Higher hematocrit levels for dialysis patients
- Hematuria



- intrathecal morphine for LPHS, 629-631
- macroscopic, IgAN and, 340-342
- in primary FSGS, 535-538
- Hemoaccess function
  - correlation between venography, venous pressure and, 269-274
  - see also Vascular access
- Hemoconcentration, post-HD, higher HCT levels and, S1:14-16
- Hemodiafiltration, continuous venovenous, in infants and children, 17-21
- Hemodialysis (HD)
  - amyloidosis in, see Amyloidosis in HD patients
  - angiodynography of vascular access blood flow in, 22-25
  - BP in, see Blood pressure of HD patients
  - chronic intermittent, Pcr determination in patients on, 887-895
  - for CRF, see Hemodialysis for CRF
  - cutaneous  $\text{CaC}_2\text{O}_4$  deposition in, 491-497
  - effects of, on SIPA in uremia, 555-563
  - efficacy of, and improved uremic pruritus in patients on, 413-419
  - for ESRD, see Hemodialysis for ESRD
  - fast, net generation of C3a in, bioincompatibility of blood flow rates and, 896-903
- HCV infection in, see Hemodialysis, and HCV infection
- high-flux, urea rebound following, 26-29
- hypervitaminosis A and, 346-348
- IDWG in patients on, nutrition and, 579-583
- maintenance, see Maintenance hemodialysis
- need for Fe therapy in, zinc protoporphyrin and, 426-432
- post-HD hemoconcentration and higher HCT levels, S1:14-16
- vascular access for, see Vascular access
- see also Renal replacement therapy registry(ies)
- Hemodialysis (HD), and HCV infection, 572-578
  - IFN- $\alpha$  facilitating renal transplantation for patients with chronic HCV and/or HBV infection on, 40-45
- Hemodialysis (HD) for CRF
  - acid dialysate and metabolic alkalosis in, 343-345
  - lipoprotein oxidation in CRF and during, 564-571
  - long-term follow-up of PRA in, 589-592
  - see also Hemodialysis for ESRD
- Hemodialysis (HD) for ESRD
  - antioxidants and lipid levels in, 566
  - diabetic ESRD, pharmacokinetics of aminoguanidine in, 420-425
- HCV infection and, 4
  - high permeability membranes for plasma porphyrin removal in, 30-33
  - influence of, on plasma and tissue pentosidine concentrations, 445-451
  - urologic cancers in patients on, 694-700
  - vascular access clotting by heparin in, 642-647
  - see also Hemodialysis for CRF
- Hemodialysis (HD) water, quality of, 738-750
- Hemodynamics
  - hemodynamic effects of rHEPO, S1:6
  - renal, and gender-related differences in chronic renal disease progression, 519-520
  - see also Blood flow; Blood pressure
- Hemoglobin, see Hb
- Hemolytic uremic syndrome (HUS) complicating acute post-infectious GN, 336-339
- Henoch-Schönlein purpura
  - acute oliguric ATN and, 651-659
  - IgAN evolution into, 340-342
- Heparin, clotting of vascular access by, 642-647
- Hepatitis, chronic, and HCV infection in HD patients, 572-578
- Hepatitis B virus (HBV) infection
  - chronic, IFN- $\alpha$  facilitating renal transplantation in HD patients with, 40-45
  - see also Concurrent hepatitis B virus and hepatitis C virus infection
- Hepatitis C virus (HCV) infection, 3-16
  - biology of, 3-4
  - in chronic dialysis patients, 399-404
  - diagnosis of, see Diagnosis and detection, HCV infection in EMC, 12-13
  - in ESRD patients, see End-stage renal disease, HCV infection in
  - in GN, 12; see also Membranoproliferative glomerulonephritis, HCV infection in
  - in HD patients, see Hemodialysis, and HCV infection
  - IFN- $\alpha$  for, see IFN- $\alpha$  for HCV infection
  - in transplantation, see Renal transplantation, HCV infection in
  - see also Concurrent hepatitis B virus and hepatitis C virus infection
- Hereditary glomerulosclerosis (GS) in conorenal syndrome, 792-798
- Heroin-associated nephropathy (HAN), disappearance of uremia due to, 689-693
- Heterogeneity of essential hypertension, 211-213
- High-density lipoprotein(s) (HDLs), oxidation of, in CRF and during HD, 564-571
- High-density lipoprotein (HDL)-cholesterol
  - serum, effects of maintenance HD dialysate buffer composition on concentration of, 584-588
  - in type II diabetes, 838, 839
- High-flux hemodialysis (HD), urea rebound following, 26-29
- High permeability membranes for plasma porphyrin removal in ESRD, 30-33
- Higher hematocrit (HCT) levels for dialysis patients, S1:1-17
  - adapting dialysis unit to, S1:12-17
  - cardiac function and, S1:3-7
  - introduction to, S1:1-2
  - outcome with, S1:8-11
- Hippurin, effects of, on plasma fluorescein binding by albumin and TCFER in DM-associated ESRD, 543-547
- Histamine in HD patients with uremic pruritus, 416
- Histology, see Renal histology
- HIV (human immunodeficiency virus)
  - rHuEPO for ESRD patients on maintenance HD and infected with, 904-909
  - see also AIDS; HIVAN
- HIVAN (human immunodeficiency virus-associated nephropathy), disappearance of uremia due to, 689-693
- HLA (human leukocyte antigen) association with karyomegalic interstitial nephritis, 242-252

- $H_2O_2$  (superoxide) production by peritoneal macrophages in CAPD, low-Ca dialysate and, 754, 755
- Home/self-care dialysis utilization in Canada, 138-140
- Homeostasis, Na/volume, ACE inhibitors effects on, 84-85
- HPTH, *see* Hyperparathyroidism
- HRQL (health-related quality of life) associated with rEPO in predialysis chronic renal disease patients, 543-554
- HTN, *see* Hypertension
- Human immunodeficiency virus, *see* HIV
- Human leukocyte antigen (HLA) association with karyomegalic interstitial nephritis, 242-252
- HUS (hemolytic uremic syndrome) complicating acute post-infectious GN, 336-339
- Hyalinosis in primary FSGS, prognosis and, 854-852
- Hydralazine, effects of, on PRF in hypertension, 910-917
- 18-Hydroxycorticosterone, plasma and serum, in hypokalemic hypertension, 830
- 25-Hydroxyvitamin D in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 224
- Hypercalcemia  
     familial hypocalciuric, extracellular  $Ca^{2+}$ -sensing receptor in, 506-513  
     and hypervitaminosis A in HD patients, 346-348
- Hypercalciuria, absorptive, nonacidotic proximal tubulopathy with, 222-227
- Hypercellularity, mesangial, in primary FSGS, prognosis and, 854-852
- Hypercholesterolemia in renal transplantation, lovastatin and nicotinic acid effects on, 616-622
- Hypercreatinemia in essential hypertension, 213
- Hyperlipidemia in renal transplantation, lovastatin and nicotinic acid effects on, 616-622
- Hyperparathyroidism (HPTH)  
     pulse oral calcitriol for, in CAPD patients, 291-296  
     secondary, *see* Chronic renal failure, secondary HPHT and severe neonatal, extracellular  $Ca^{2+}$ -sensing receptor in, 506-513
- Hyperphosphatemia, and secondary HPTH in CRF, 664-668
- Hypertension (HTN)  
     and cardiac function in dialysis patients, S1:5  
     chronic renal disease with, reduced renal mass and renal ET-1 production in, 918-923  
     familial hyperuricemia with precocious gout and, 235-241  
     and 5/6 nephrectomy, effects of flaxseed and flax oil diets on, 320-329  
     and gender-related differences in chronic renal disease progression, 520-521  
     hypokalemic, in Liddle's syndrome, 829-835  
     and late acute rejection of renal transplant, 776  
     LBW hypothesis on racial differences in NIDDM, ESRD and, 350-356  
     management of, *see* Hypertension management  
     mild-to-moderate, renal impairment in, 212-214  
     PRF in, oral  $CaCO_3$  effects on, 910-917  
     with type II diabetes, 838, 839  
     *see also* Hypertensive nephrosclerosis
- Hypertension (HTN) management  
     with enalapril in chronic renal disease, effects of, on renal ET-1 production, 918-923  
     in microalbuminuria of DM, 112  
     in prevention of progressive nephropathy in nondiabetic patients, 104-105
- see also* Hypertensive nephrosclerosis and specific antihypertensive agents
- Hypertensive nephrosclerosis, 207-221  
     animal models of, 208-210  
     nephrosclerosis defined, 208  
     spectrum of renal disease in hypertension and, 211-218
- Hypertrophy, left ventricular, in dialysis patients, HCT level and, S1:3-7
- Hyperuricemia, familial, with precocious gout and hypertension, 235-241
- Hypervitaminosis A in HD patients, 346-348
- Hypocalcemia, and secondary HPTH in CRF, 664
- Hypocalciuric variant of Bartter's syndrome, *see* Gitelman's syndrome, as hypocalciuric variant of Bartter's syndrome
- Hypocalciuric hypercalcemia, familial, extracellular  $Ca^{2+}$ -sensing receptor in, 506-513
- Hypocomplementemia in MPGN type II, paramesangial glomerular deposits correlated with, 853-861
- Hypokalemia  
     in Bartter's syndrome, *see* Bartter's syndrome  
     in Gitelman's syndrome, 637-641
- Hypokalemic hypertension in Liddle's syndrome, 829-835
- Hypomagnesemia in Bartter's and Gitelman's syndromes, 637-641
- Hypophosphatemia, absorptive hypercalciuria and, in nonacidotic proximal tubulopathy, 222-227
- Hypotension in outpatients undergoing renal biopsy, 877
- Hypothalamic arginine vasopressin (AVP) mRNA (messenger ribonucleic acid) in puromycin-induced NS, 60
- Hypothyroidism, acute CsA nephrotoxicity in renal transplantation with, 503-505
- Hypouricemia, renal, prevention of exercise-induced ARF and, with allopurinol, 937-946
- IDDM (insulin-dependent diabetes mellitus), *see* Diabetes mellitus
- Idiopathic membranous glomerulopathy, therapies of, reviewed, 862-875
- IDWG (interdialytic weight gain), and nutrition in HD patients, 579-583
- IFN- $\alpha$ , *see* Interferon- $\alpha$  for HCV infection
- Ig (immunoglobulin), therapy with IV, ARF associated with, 228-234
- IgA- $\kappa$  (immunoglobulin A- $\kappa$ ) crystalline deposition disease, recurrence of, after renal transplantation, 75-78
- IgA (immunoglobulin A) nephropathy (IgAN; Berger's disease)  
     ECM receptor distribution in, 682  
     evolution of, into Henoch-Schönlein purpura, 340-342
- IgAN, *see* IgA nephropathy
- IgE (immunoglobulin E) in HD patients with uremic pruritus, 416
- IgM (immunoglobulin M), mesangial, in primary FSGS, prognosis and, 854-852
- IL-1, *see* Interleukin-1, biological control of
- Immunodeficiency  
     common variable, in renal transplantation with severe bacterial infections, 947-951  
     *see also* AIDS
- Immunodiagnosis of HCV infection, 4

- with RIBA 3.0 in HD patients, 572-578
- Immunoglobulin, *see entries beginning with acronym: Ig*
- Immunohistochemistry
  - of karyomegalic interstitial nephritis, 245-246
  - of TI lesions, 480-481
- Immunohistology of familial GN, 782
- IN, *see* Interstitial nephritis
- Incidence
  - of ESRD by age, diabetes, and race, 714-721
  - of pneumoperitoneum in PD patients, 298
  - of RRT patients, *see* Incidence of RRT patients
  - see also* Prevalence and specific conditions
- Incidence of RRT patients
  - in Canada, 137
  - in Europe, 178
  - in France, 189-190
  - in Lombardy, 198
  - in New Zealand and Australia, 167-169
  - in U.S., 121, 122, 127
- Infants, *see* Children
- Infections, *see* Bacterial infections; Sepsis and specific infections
- Inferior vena cava (IVC) cannulation, percutaneous translumbar, with double-lumen silicone catheters in HD, 732-737
- Inflammatory injury, *see* Interleukin-1, biological control of; Tumor necrosis factor- $\alpha$ , biological control of and specific inflammatory injuries
- Insulin-dependent diabetes mellitus, *see* Diabetes mellitus
- Integrins, distribution of, in GN, 680-688
- Interdialytic weight gain (IDWG), and nutrition in HD patients, 579-583
- Interferon- $\alpha$  (IFN- $\alpha$ ) for HCV infection
  - for MPGN associated with HCV infection, 67-69
  - renal transplantation for HD patients with chronic HCV and/or HBV infection facilitated by, 40-45
- Interleukin-1 (IL-1), biological control of, 958-962
  - with anti-inflammatory interleukins, 961
  - characteristics and role of, 958-959
- IL-1 receptor antagonists and, 959-961
  - summary on, 961-962
- Intermittent hemodialysis (HD), chronic, Pcr determination in patients on, 887-895
- Interstitial nephritis (IN)
  - acute ticlopidine-induced, 934-936
  - karyomegalic, 242-252
  - and TI lesions in young subjects, 478-488
  - tumefactive megalocytic, with *E coli* bacteremia, 928-933
- Intracellular Na<sup>+</sup> (sodium), racial variation in transport of, hypertensive nephrosclerosis and, 212
- Intracranial saccular aneurysms, ADPKD and, 70-74
- Intrarenal extramedullary erythropoiesis in renal allograft fine-needle aspirates, 46-50
- Intrathecal morphine for LPHS, 629-631
- Intravascular ultrasound (IVUS) imaging of thrombus formation in double-lumen catheter, 597-602
- Intravenous Ig (IVIg), ARF associated with, 228-234
- Intrinsic renal diseases mimicking hypertensive nephrosclerosis, 214-215
- <sup>14</sup>C-Inulin, effects of flaxseed and flax oil diets on clearance of, in 5/6 nephrectomy, 323
- Ion transport
  - tubular, Bartter's syndrome due to disorders of, 818-819
  - see also* specific ions
- Ionized calcium, *see* Ca<sup>2+</sup>; Ca<sub>i</sub><sup>2+</sup>
- Iron, *see* Fe
- Ischemic heart disease, and cardiac function in dialysis patients, S1:5
- IVC (inferior vena cava) cannulation, percutaneous translumbar, with double-lumen silicone catheters in HD, 732-737
- IVIg (intravenous immunoglobulin) therapy, ARF associated with, 228-234
- IVUS (intravascular ultrasound) imaging of thrombus formation in double-lumen catheter, 597-602
- Japan, RRT in, 151-164
- K and K<sup>+</sup> (potassium)
  - in Gitelman's syndrome, 826
  - in metabolic alkalosis, 344
  - plasma, *see* Plasma K
  - serum, *see* Serum K
  - see also* Hypokalemia; Hypokalemic hypertension; Na<sup>+</sup>, K<sup>+</sup> ATPase
- Kallikrein, racial variation in urinary excretion of, hypertensive nephrosclerosis and, 212
- Karyomegalic interstitial nephritis (IN), 242-252
- 6-Keto prostaglandin F1 $\alpha$  (PGF1 $\alpha$ ), urinary, flaxseed and flax oil diet effects on, in 5/6 nephrectomy, 324, 327
- Kt/V urea
  - in diabetic CRF, 441
  - in HD patients, *see* Kt/V urea in HD
  - in HIV-infected patients on maintenance HD, 906
  - and rhEPO and Fe therapy, 434
- Kt/V urea in HD
  - and IDWG, 580, 581
  - and improvement of uremic pruritus, 413-419
  - and urea rebound following high-flux HD, 26-29
- Lag phase in lipoprotein oxidation in CRF and during HD, 564-571
- Late acute rejection of renal transplant, prognostic value of EPO serum levels in, 775-780
- LBW (low birth weight) hypothesis on racial differences in HTN, NIDDM, and ESRD, 350-356
- LDLs (low-density lipoproteins), oxidation of, in CRF and during HD, 564-571
- Left ventricular hypertrophy (LVH) in dialysis patients, HCT levels and, S1:3-7
- Left ventricular systolic dysfunction (LVSD), severe, CAPD for ESRD with, 761-768
- Leukocyte(s)
  - polymorphonuclear, nifedipine effects on metabolism and function of, in diabetic CRF, 440-444
  - see also* Leukocyte antigen; Leukocyte count; Macrophages
- Leukocyte antigen, human, association of, with karyomegalic interstitial nephritis, 242-252
- Leukocyte count
  - during fast HD, 897-898
  - and lipoprotein oxidation in CRF during HD, 567, 568
- LHCDD (light and heavy chain deposition disease), recurrent

- Ig A- $\kappa$  crystalline deposition disease after renal transplantation as, 75-78
- Liddle's syndrome  
hypokalemic hypertension in, 829-835  
as public health menace, 924-927
- Light and heavy chain deposition disease (LHCDD), recurrent Ig A- $\kappa$  crystalline deposition disease after renal transplantation as, 75-78
- Lignans in flax oil, effects of, in 5/6 nephrectomy, 320-329
- Limulus amebocyte lysate test of HD water, 738-750
- $\alpha$  (alpha)-Linoleic acid in flax oil, effects of, in 5/6 nephrectomy, 320-329
- Lipids  
effects of flaxseed and flax oil diets on, in 5/6 nephrectomy, 320-329  
estrogen interaction with, in chronic renal disease, 523-524  
levels of, in CRF patients during HD, 566  
lovastatin and nicotinic acid effects on hyperlipidemia in renal transplantation, 616-622  
*see also specific lipids*
- Lipopolysaccharide (LPS), effects of, on endotoxin-induced ARF, 51-57
- Lipoprotein(s), oxidation of, in CRF and during HD, 564-571
- Lipoprotein glomerulopathy with new apolipoprotein E phenotype, 952-953
- Lithium therapy, long-term, ACE inhibitors responsible for renal dysfunction in patients on, 82-87
- Living-related donors (LRDs), allograft survival with race and, 623-628  
transplant patient and, in Canada, 143, 147, 149-150
- Loin pain hematuria syndrome (LPHS), intrathecal morphine for, 629-631
- Lombardy (Italy), RRT in, 196-205
- Long-term follow-up of PRA in CRF patients on HD, 589-592
- Long-term lithium therapy, ACE inhibitors responsible for renal dysfunction in patients on, 82-87
- Long-term tunnelled silicone catheters, guidewire exchange in management of sepsis related to, 593-596
- Lovastatin, effects of nicotinic acid and, in renal transplantation, 616-622
- Low birth weight (LBW) hypothesis on racial differences in HTN, NIDDM, and ESRD, 350-356
- Low-calcium (Ca) dialysate in CAPD, 452-460  
effects of, on peritoneal macrophage function, 751-760
- Low-density lipoproteins (LDLs), oxidation of, in CRF and during HD, 564-571
- LPHS (loin pain hematuria syndrome), intrathecal morphine for, 629-631
- LPS (lipopolysaccharide), effects of, on endotoxin-induced ARF, 51-57
- LRDs, *see* Living-related donors, allograft survival with
- LVH (left ventricular hypertrophy) in dialysis patients, HCT levels and, S1:3-7
- LVSD (left ventricular systolic dysfunction), severe, CAPD for ESRD with, 761-768
- Lymphocytes, T, in TI lesions, 478-488
- $\beta_2$ M, *see*  $\beta_2$ -Microglobulin
- Macrophage(s), peritoneal, effects of low-Ca dialysate in CAPD on function of, 751-760
- Macrophage proliferation in tumefactive megalocytic interstitial nephritis with *E coli* bacteremia, 928-933
- Macroscopic hematuria, IgAN and, 340-342
- Madin-Darby canine kidney (MDCK) cell proliferation, cyst fluid in ADPKD stimulating, 471-477
- Magnesium, *see* Mg
- Magnetic resonance angiography (MRA) of RAS in PRF, 701-709
- Maintenance hemodialysis (HD)  
dialysate in, *see* Maintenance hemodialysis, dialysate in outcome of CABG and PTCA in patients on, 281-290  
rHuEPO for HIV-infected ESRD patients on, 904-909
- Maintenance hemodialysis (HD), dialysate in acid dialysate and metabolic alkalosis in CRF patient on, 343-345  
effects of dialysate buffer composition on serum HDL-cholesterol concentrations, 584-588
- Malacoplakia, and tumefactive megalocytic interstitial nephritis with *E coli* bacteremia, 928-933
- Malignancy, *see* Cancers
- Malnutrition, *see* Nutrition
- MAP (mean arterial pressure), *see* Blood pressure
- Marital status, and completion of ADs by dialysis patients, 263
- Mass transfer area coefficient, optimization of dialysate, during APD, 603-611
- MDCK (Madin-Darby canine kidney) cell proliferation, cyst fluid in ADPKD stimulating, 471-477
- Mean arterial pressure, *see* Blood pressure
- Megalocytic interstitial nephritis, tumefactive, with *E coli* bacteremia, 928-933
- Membranoproliferative glomerulonephritis (MPGN)  
ECM receptor distribution in, 682  
HCV in, *see* Membranoproliferative glomerulonephritis, HCV infection in  
with primary Sjögren's syndrome, 632-636
- Membranoproliferative glomerulonephritis (MPGN), HCV infection in  
associated with HCV infection responsive to IFN- $\alpha$ , 67-69  
cryoglobulinemic, *see* Cryoglobulinemic glomerulonephritis, HCV infection and
- Membranoproliferative glomerulonephritis (MPGN) type II, paramesangial glomerular deposits in, correlated with hypocomplementemia, 853-861
- Membranous glomerulonephritis (MGN), tubulointerstitial lesions in, proteinuria and, 375-379
- Membranous glomerulopathy, idiopathic, therapies of, reviewed, 862-875
- Men  
incidence rates of ESRD attributed and not attributed to DM in, 715-716  
*see also* Sex
- Mesangial hypercellularity in primary FSGS, prognosis and, 854-852
- Mesangial IgM (immunoglobulin M) in primary FSGS, prognosis and, 854-852
- Messenger ribonucleic acid (mRNA), hypothalamic AVP, in puromycin-induced NS, 60

- Meta-analysis of idiopathic membranous glomerulopathy therapies, 862-875
- Metabolic alkalosis  
in Bartter's syndrome, *see* Bartter's syndrome  
in CRF, acid dialysate and, 343-345
- Metabolism  
of ARF, parenteral nutrition and, 96-97  
vitamin D, in secondary HPTH in CRF, 668-672
- Metanephrines, urinary excretion of, in hypokalemic hypertension, 830
- Methodological obstacles to epidemiologic study of ESRD, 724-727
- Methylprednisolone  
PKD progression retarded with, 302-313  
pulse, for palpable purpura and acute oliguric GN, 652-659
- Mg (magnesium)  
in HD patients with uremic pruritus, 416  
hypomagnesemia in Bartter's and Gitelman's syndromes, 637-641  
plasma, in Gitelman's syndrome, 826
- MGN (membranous glomerulonephritis), tubulointerstitial lesions in, proteinuria and, 375-379
- Microalbuminuria in DM, 107-112  
background to, 108-110  
existing guidelines on, 107-108  
screening for, 110-111  
therapy of, 111-112
- Microangiopathy, renal, in primary APS, captopril and aspirin for, 486-488
- $\beta_2$  (beta<sub>2</sub>)-Microglobulin ( $\beta_2$ M)  
in HD patients with uremic pruritus, 416  
in HD-related amyloidosis, 807-809  
in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 223
- Microvasculature, renal, effects of hypertension on, 211
- Mild-to-moderate hypertension, renal impairment in, 212-214
- Minimal change disease presenting with ATN, 648-650
- Mixed cryoglobulinemia, essential, HCV infection in, 12-13
- Molecular detection of HCV infection in ESRD patients, 4-5
- Monocytes (mononuclear cells) in TI lesions, 478-488
- Monophosphate, cyclic adenosine, cyst fluid in ADPKD stimulating accumulation of, 471-477
- Morbidity  
associated with CAPD for ESRD with severe LVSD, 766  
*see also specific conditions*
- Morphine, intrathecal, for LPHS, 629-631
- Morphology  
of cryoglobulinemic GN, 362  
of familial GN, 783-785
- Mortality  
in familial ADPKD, 370-374  
and 5/6 nephrectomy, 322  
with RRT, *see* Mortality with RRT  
*see also* Death and *specific conditions*
- Mortality with RRT  
in Australia and New Zealand, 171, 172, 174-175  
in France, 194-195  
with HD, BP and, 405-412  
in Japan, 156-159, 162-163  
in Lombardy, 198  
in U.S., 128, 129
- MPGN, *see* Membranoproliferative glomerulonephritis; Membranoproliferative glomerulonephritis type II
- MRA (magnetic resonance angiography) of RAS in PRF, 701-709  
mRNA (messenger ribonucleic acid), hypothalamic AVP, in puromycin-induced NS, 60
- Na (and Na<sup>+</sup>) (sodium)  
in metabolic alkalosis, 344  
plasma, *see* Plasma Na  
racial variation in intracellular transport of, hypertensive nephrosclerosis and, 212  
serum, *see* Serum Na  
*see also* Na channels; Na<sup>+</sup>,K<sup>+</sup> ATPase; Na/volume homeostasis
- Na (sodium) channels in Liddle's syndrome, 829-825
- Na<sup>+</sup>,K<sup>+</sup> ATPase (sodium,potassium adenosine triphosphatase), racial variation in, hypertensive nephrosclerosis and, 212
- Na (sodium)/volume homeostasis, ACE inhibitors effects on, 84-85
- NADH (nicotinamide adenine dinucleotide), effects of antioxidants on, in endotoxin-induced ARF, 55
- NE (norepinephrine), serum and plasma, in hypokalemic hypertension, 830
- Necrosis, *see* Acute tubular necrosis
- Neonatal severe hyperparathyroidism, extracellular Ca<sup>2+</sup>-sensing receptor in, 506-513
- Nephrectomy, 5/6, effects of flaxseed and flax oil diets in, 320-329
- Nephritic factor in MPGN type II, 853-861
- Nephritis, *see* Glomerulonephritis; Interstitial nephritis
- Nephrolithiasis in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 222-227
- Nephropathy, *see specific conditions*
- Nephrosclerosis, *see* Hypertensive nephrosclerosis
- Nephrotic syndrome (NS)  
ECM receptor distribution in nonproliferative glomerular diseases with, 684  
in idiopathic membranous glomerulopathy, 867, 870-871  
with minimal change disease, 648-650  
MPGN with primary Sjögren's syndrome and, 632-636  
primary FSGS and, 534-542  
puromycin-induced, AVP gene expression in, 58-62  
unilateral renal dysplasia and, 88-95  
urinary Fe speciation in, 314-319
- Nephrotoxicity, acute CsA, in hypothyroidic renal transplantation recipient, 503-505
- New Zealand, RRT in, 165-175
- Niacin (nicotinic acid), effects of lovastatin and, in renal transplantation, 616-622
- Nicotinamide adenine dinucleotide (NADH), effects of antioxidants on, in endotoxin-induced ARF, 55
- Nicotinic acid (niacin), effects of lovastatin and, in renal transplantation, 616-622
- NIDDM, *see* Non-insulin-dependent diabetes mellitus
- Nifedipine, effects of, on metabolism and function of PMNLs, in diabetic CRF patients on HD, 440-444
- Nitrogen, *see* Urea nitrogen



- Nonacidotic proximal tubulopathy with absorptive hypercalciuria, 222-227
- Nondiabetic patients, prevention of progressive nephropathy in, 104-105
- Nondialyzed chronic renal failure (CRF) patients  
dietary protein intake of, urea output and urea generation rate and, 887-895  
oral  $\text{CaCO}_3$  for secondary HPHT in, 879-886
- Non-human immunodeficiency virus (HIV) patients, severe ARF in 392, 393
- Non-insulin-dependent diabetes mellitus (NIDDM; type II diabetes)  
factors associated with albuminuria, 836-844  
*see also* Diabetes mellitus; Non-insulin-dependent diabetes mellitus, ESRD and
- Non-insulin-dependent diabetes (NIDDM; type II diabetes), ESRD and  
familial predisposition to ESRD in African-Americans with NIDDM, 710-713  
LBW hypothesis on racial differences in HTN, ESRD and, NIDDM, 350-356  
*see also* Microalbuminuria in DM
- Norepinephrine (NE), serum and plasma, in hypokalemic hypertension, 830
- Normal kidney, ECM receptor distribution in, 682
- Normal prostaglandinuria  $\text{E}_2$  in Gitelman's syndrome, as hypocalciuric variant of Bartter's syndrome, 824-828
- Normalized protein catabolic rate (nPcr) in HD patients with uremic pruritus, 413-419
- Nosocomial transmission of HCV infection  
in chronic dialysis patients, 399-404  
in ESRD patients, 7-8
- Nosology, *see* Classification
- nPcr (normalized protein catabolic rate) in HD patients with uremic pruritus, 413-419
- NS, *see* Nephrotic syndrome
- Nutrition  
in HD patients, IDWG and, 579-583  
*see also* Diet; Parenteral nutrition in ARF
- Obstruction  
pelvic outlet, with osteogenesis imperfecta, 489-491  
urinary, and severe ARF in AIDS, 390-398  
 $1,25(\text{OH})_2\text{D}_3$ , *see*  $1,25$ -Dihydroxyvitamin  $\text{D}_3$
- OI (osteogenesis imperfecta), unusual complications with, 489-491
- Oliguric glomerulonephritis (GN), acute, palpable purpura and, 651-659
- Oral  $\text{CaCO}_3$  (calcium carbonate), effects of, on PRF in hypertension, 910-917
- Oral calcitriol, pulse, limitations of, in CAPD patients, 291-296
- Oral Fe (iron) therapy with rhEPO, 433-439
- Organisms  
responsible for polymicrobial peritonitis in CAPD, 462  
*see also* entries beginning with term: Bacterial and specific organisms
- Osteocalcin, and low-Ca dialysate in CAPD, 455-457
- Osteodystrophy, *see* Renal osteodystrophy in CAPD
- Osteogenesis imperfecta (OI), unusual complications with, 489-491
- Outcome  
of ARF, *see* Outcome, ARF  
of CABG and PTCA in maintenance HD and/or PD patients, 281-290  
of CAPD for ESRD with severe LVSD, 763-765  
of chronic renal disease with rhEPO therapy, 550-551  
ESRD, and epidemiologic study of kidney disease, 724, 727  
with higher HCT levels in dialysis patients, S1:8-11  
of idiopathic membranous glomerulopathy, 866, 867, 869-871  
polymicrobial peritonitis, in CAPD, 461-464  
of renal transplantation in women of child-bearing age, 465-470  
of urologic cancers in uremia, 697  
*see also* Mortality; Survival and specific conditions
- Outcome, ARF  
due to djenkolism, 65  
of severe ARF in AIDS, 390-398
- Outpatient procedure, renal biopsy as, 876-878
- Oxalate, calcium, cutaneous deposition of, in HD patients, 492-497
- Oxalosis, HD, 491-497
- Oxidation, lipoprotein, in CRF and during HD, 564-571
- P (phosphate)  
in calciphylaxis, 499  
in HD patients with uremic pruritus, 416  
hyperphosphatemia in secondary HPTH in CRF, 664-668  
and hypervitaminosis A in HD patients, 347  
hypophosphatemia in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 222-227  
and low-Ca dialysate in CAPD, 452-460  
oxalosis of HD and, 496
- $\text{PCO}_2$   
in Bartter's and Gitelman's syndromes, 638  
in metabolic alkalosis, 344
- $\text{PO}_2$   
in Bartter's and Gitelman's syndromes, 638  
in metabolic alkalosis, 344
- Pain  
calf, calciphylaxis presenting with, in CAPD and predialysis patients, 498-502  
intrathecal morphine for LPHS, 629-631
- Palpable purpura, and acute oliguric GN, 651-659
- Pancreas, congenital alterations of, LBW and, 351-352
- Paramesangial glomerular deposits in MPGN type II correlated with hypocomplementemia, 853-861
- Parathyroid cell(s)  
autonomous proliferation of, in secondary HPTH in CRF, 672  
sensing of extracellular  $\text{Ca}^{2+}$  by, 506-513
- Parathyroid hormone (PTH)  
in calciphylaxis, 499  
in HD patients, *see* Parathyroid hormone in HD patients  
in hypertension, effects of oral  $\text{CaCO}_3$  on, 914  
and low-Ca dialysate in CAPD, 455-457  
and nifedipine effects on PMNL function and metabolism in diabetic CRF, 440-444  
in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 224



- and rhEPO and Fe therapy, 434  
*see also* Hyperparathyroidism
- Parathyroid hormone (PTH) in HD patients  
with hypervitaminosis A, 347  
with uremic pruritus, 416
- Parenteral nutrition in ARF, 96-102  
complications of, 98-100  
metabolism of ARF and, 96-97  
prescribing, 100-101  
studies of, 97-99
- Pathology, pathogenesis, and pathophysiology  
of Bartter's syndrome, 816-819  
of cryoglobulinemic GN, 363-365  
of MGN, 376  
of NS with unilateral renal dysplasia, 91-92  
of respiratory alkalosis in CAPD patient with pulmonary disease, 80-81  
*see also specific conditions*
- Patient characteristics  
of AIDS patients with severe ARF, 391-392  
of chronic renal disease patients on rhEPO therapy, 543-554  
and death during first 90 days of dialysis, 277  
of primary FSGS patients, 535-536, 846-847  
of Japanese RRT patients, 152-153  
of maintenance HD and/or PD patients, CBGA and PTCA outcome and, 284-285  
of type II diabetes patients, 838, 839  
*see also* Age; Body mass index; Body weight; Education; Marital status; Race and ethnicity; Sex; Work status
- Patient position in APD, dialysate flow, mass transfer and, 603-611
- Patient survival with renal transplantation  
in Canada, 143-149  
comparative data on, 117  
in Japan, 159-162  
in U.S., 131
- Patient survival with RRT  
in Australia and New Zealand, 170, 173-175  
in Canada, 235, 140-146, 148  
with CBGA and PTCA in maintenance HD and/or PD patients, 285-288  
in France, 192-194  
with HD, BP and, 405-412  
in Italy, 116  
in Japan, 156  
in Lombardy, 201  
in U.S., 116, 131  
*see also* Patient survival with renal transplantation
- Pcr, *see* Protein catabolic rate
- PCR (polymerase chain reaction), HCV RNA detection by, 9-10, 572-578
- PD, *see* Peritoneal dialysis
- Pediatric conditions and interventions, *see* Children
- Pelvic outlet obstruction with osteogenesis imperfecta, 489-491
- Pentosidine, tissue and plasma, dialysis modality for ESRD and concentration of, 445-451
- Percutaneous translumbar inferior vena cava (IVC) cannulation with double-lumen silicone catheters in HD, 732-737
- Percutaneous transluminal coronary angioplasty (PTCA), outcome of CABG and, in maintenance HD and/or PD patients, compared, 281-290
- Perforation, visceral, pneumoperitoneum in HD patients and, 297-301
- Performance status of renal transplant recipients, *see* Rehabilitation of RRT patients
- Peritoneal dialysis (PD)  
automated, optimization of dialysate flow and mass transfer during, 603-611  
for ESRD, influence of, on plasma and tissue pentosidine concentrations, 445-451  
outcome of CABG and PTCA in patients on, 281-290  
pneumoperitoneum in, 297-301
- Pseudomonas*, in PD, 769-774  
*see also* Continuous ambulatory peritoneal dialysis; Continuous cycling peritoneal dialysis
- Peritoneal macrophages, effects of low-Ca dialysate in CAPD on function of, 751-760
- Peritonitis  
in CAPD, *see* Peritonitis in CAPD  
in CCPD, gram-positive, trough serum vancomycin levels and relapse of, 611-615
- Pseudomonas*, in PD, 769-774
- Peritonitis in CAPD  
gram-positive, trough serum vancomycin levels and relapse of, 611-615  
polymicrobial, outcome of, 461-464
- PGs, *see* entries beginning with term: Prostaglandin
- pH  
blood, in Gitelman's syndrome, 826  
plasma, in Bartter's and Gitelman's syndromes, 638
- Phagocytosis  
in diabetic CRF, effects of nifedipine on, 440-444  
by peritoneal macrophages in CAPD, low-Ca dialysate and, 755-756
- Phalanges, cone-shaped epiphyses of, in conorenal syndrome, 792-798
- Pharmacokinetics, aminoguanidine, in ESRD patients on HD, 422-425
- Phenotype, apolipoprotein E, lipoprotein glomerulopathy with new, 952-953
- Phosphatase, *see* Alkaline phosphatase
- Phosphate, *see* P
- Phosphate binder,  $\text{CaCO}_3$  as, *see*  $\text{CaCO}_3$
- Phospholipids, renal, effects of flaxseed and flax oil diets on clearance of, in 5/6 nephrectomy, 323-324, 326, 327
- Phosphorus  
effects of pulse oral calcitriol on, in CAPD patients, 291-296  
plasma, in diabetic CRF, nifedipine effects on PMNL function and metabolism and, 441  
serum, in Bartter's and Gitelman's syndromes, 638
- PKD, *see* Polycystic kidney disease
- Placenta, effects of, on GN with anti-GBM antibody during pregnancy, 330-335
- Plasma advanced glycation end-products (AGEs), dialysis modality for ESRD and concentration of, 445-451
- Plasma aldosterone in hypokalemic hypertension, 830
- Plasma Ca (calcium)  
in diabetic CRF, nifedipine effects on PMNL function and metabolism in, 441

- in Gitelman's syndrome, 826
- total, in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 224
- Plasma catecholamines in hypokalemic hypertension, 830
- Plasma cholesterol, effects of flaxseed and flax oil diets on, in 5/6 nephrectomy, 323, 324
- Plasma Cl (chloride)
  - in Gitelman's syndrome, 826
  - in hypokalemic hypertension, 830
  - in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 223
- Plasma cortisol in hypokalemic hypertension, 830
- Plasma creatinine (Cr; CRE)
  - in familial hyperuricemia, 237
  - in Gitelman's syndrome, 826
  - in hypokalemic hypertension, 830
  - in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 223
- Plasma 1,25-dihydroxyvitamin D<sub>3</sub> [calcitriol; 1,25(OH)<sub>2</sub>D<sub>3</sub>]
  - in nonacidotic proximal tubulopathy with hypercalcemia, 224
- Plasma dopamine (D) in hypokalemic hypertension, 830
- Plasma epinephrine (E) in hypokalemic hypertension, 830
- Plasma flow, renal, in hypertension, effects of oral CaCO<sub>3</sub> on, 914
- Plasma fluorescein binding by albumin, TCFER and, in DM-associated ESRD, 543-547
- Plasma HCO<sub>3</sub> (bicarbonate)
  - in Bartter's syndromes, 638
  - in Gitelman's syndrome, 638, 826
  - in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 223
- Plasma 18-hydroxycorticosterone in hypokalemic hypertension, 830
- Plasma 25-hydroxyvitamin D in nonacidotic proximal tubulopathy with hypercalciuria, 224
- Plasma K (potassium)
  - in hypokalemic hypertension, 830
  - in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 223
- Plasma Na (sodium)
  - in Gitelman's syndrome, 826
  - in hypokalemic hypertension, 830
  - in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 223
- Plasma norepinephrine (NE) in hypokalemic hypertension, 830
- Plasma P (phosphate) in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 224
- Plasma parathyroid hormone (PTH) in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 224
- Plasma pentosidine, dialysis modality for ESRD and concentration of, 445-451
- Plasma pH in Bartter's and Gitelman's syndromes, 638
- Plasma phosphorus in diabetic CRF, nifedipine effects on PMNL function and metabolism in, 441
- Plasma porphyrin, high permeability HD membranes for removal of, in ESRD, 30-33
- Plasma protein in Gitelman's syndrome, 826
- Plasma renin
  - in hypokalemic hypertension, 830
- see also* Plasma renin activity
- Plasma renin activity (PRA)
  - in Bartter's and Gitelman's syndromes, 638
  - in HD patients, long-term follow-up of, 589-592
  - in hypertension, effects of oral CaCO<sub>3</sub> on, 914
  - in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 223
  - racial variation in, hypertensive nephrosclerosis and, 212
- Plasma total Ca (calcium) in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 224
- Plasma urate in familial hyperuricemia, 237
- Plasma uric acid in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 223
- Plasma volume, racial variation in, hypertensive nephrosclerosis and, 212
- Plasmapheresis for palpable purpura and acute oliguric GN, 652-659
- Platelet aggregation, shear-induced, in uremia, effects of HD on, 555-563
- Platelet membrane glycoprotein (GP), and effects of HD on SIPA in uremia, 555-563
- PMNLs (polymorphonuclear leukocytes), nifedipine effects on metabolism and function of, in diabetic CRF, 440-444
- Pneumoperitoneum in PD patients, 297-301
- Policy-related obstacles to epidemiologic study of ESRD, 723-724
- Political factors, impact of, on RRT programs, 117-118
- Political structures, Canadian, RRT and, 134
- Polyacrylonitrile membranes for plasma porphyrin removal in ESRD, 30-33
- Polycystic kidney disease (PKD)
  - autosomal dominant, *see* Autosomal dominant polycystic kidney disease
  - methylprednisolone retarding progression of, 302-313
- Polymerase chain reaction (PCR), HCV RNA detection by, 9-10, 572-578
- Polymicrobial peritonitis in CAPD, outcome of, 461-464
- Polymorphonuclear leukocytes (PMNLs), nifedipine effects on metabolism and function of, in diabetic CRF, 440-444
- Polysulfone membranes, lipoprotein oxidation with, 566, 567
- Porphyrin, plasma, high permeability HD membranes for removal of, in ESRD, 30-33
- Posthemodialysis hemoconcentration, higher HCT levels and, S1:14-16
- Postinfectious glomerulonephritis (GN), HUS complicating, 336-339
- Posttransplant conditions and interventions, *see* Renal transplantation
- Potassium, *see* K and K<sup>+</sup>
- PRA, *see* Plasma renin activity
- Precocious gout, familial hyperuricemia with hypertension and, 235-241
- Predialysis patients
  - BUN and IDWG of, in HD patients, 580
  - calciphylaxis presenting with calf pain in, 498-502
  - with chronic renal disease, HRQL associated with rhEPO in, 543-554
- Predisposition, *see* Familial predisposition; Risk and risk factors

- Prednisone, FSGS therapy with, 534-542
- Pregnancy
- GN with anti-GBM antibody during, effects of placenta on, 330-335
- renal transplantation and, 465-470
- Prescription of parenteral nutrition in ARF, 100-101
- Prevalence
- of chronic renal disease, gender and, 515-516
- of HCV antibodies and HCV RNA in MPGN, 365
- of RRT patients, *see* Prevalence of RRT patients
- see also* Incidence and specific conditions
- Prevalence of RRT patients
- in Canada, 138
- in France, 189-190
- in New Zealand and Australia, 169-170
- in U.S., 125, 127
- Prevention
- of chronic renal disease progression, 103-106
- of ESRD, epidemiologic study and, 728-730
- of renal hypouricemia and exercise-induced ARF with allopurinol, 937-946
- PRF, *see* Progressive renal failure
- Primary antiphospholipid syndrome (APS), captopril and aspirin for renal microangiopathy in, 486-488
- Primary focal segmental glomerulosclerosis (FSGS)
- adult, histology and prognosis of, 845-852
- clinical presentation, course, and response to therapy of, 534-542
- Primary renal disease(s)
- in CAPD patients, *see* Primary renal diseases in CAPD patients
- and death during first 90 days of dialysis, 277-278
- nephrosclerosis as, 216-217
- in RRT patients, *see* Primary renal diseases in RRT patients
- see also* specific conditions
- Primary renal diseases in CAPD patients
- low-Ca dialysate and, 454
- and polymicrobial peritonitis, 462
- with urologic cancers, 697
- Primary renal diseases in RRT patients
- CABG and PTCA outcome in maintenance HD and/or PD patients and, 284
- Canadian, 136-138, 142, 143, 145, 147-149
- and completion of ADs by dialysis patients, 263
- in Lombardy, 198
- in New Zealand and Australia, 172, 173
- in newly accepted patients, 116
- U.S., 128
- see also* Primary renal diseases in CAPD patients
- Primary Sjögren's syndrome, MPGN with, 632-636
- Probenecid, effects of, on renal hypouricemia and exercise-induced ARF, 939
- Prognosis
- of HD patients, BP and, 405-412
- of primary FSGS, *see* Prognosis, primary FSGS
- and serum EPO levels in late acute rejection of renal transplant, 775-780
- of severe ARF in AIDS patients, 394-395
- see also* Outcome
- Prognosis, primary FSGS
- clinical features and, 538-539
- histology and, 845-852
- Progression
- of chronic renal disease, *see* Chronic renal disease progression
- of IgAN to Henoch-Schönlein purpura, 340-342
- of PKD, methylprednisolone retarding, 302-313
- see also* Progressive renal failure; Rapidly progressive glomerulonephritis
- Progressive glomerulonephritis, *see* Rapidly progressive glomerulonephritis
- Progressive renal failure (PRF)
- MRA of RAS in, 701-709
- oral CaCO<sub>3</sub> effects on PRF in hypertension, 910-917
- Prophylaxis, *see* Prevention
- Prostaglandin(s) (PGs)
- in Bartter's syndrome, overproduction of, 817-818
- and gender-related differences in chronic renal disease progression, 522-523
- Prostaglandin F<sub>1α</sub> (PGF<sub>1α</sub>), urinary 6-keto, flaxseed and flax oil diet effects on, in 5/6 nephrectomy, 324, 327
- Prostaglandinuria E<sub>2</sub>, normal, in Gitelman's syndrome, as hypocalciuric variant of Bartter's syndrome, 824-828
- Protein
- high permeability membranes for removal of protein-bound porphyrins in ESRD, 30-33
- intake of, by nondialyzed CRF patients, urea generation rate and urea output and, 887-895
- plasma, in Gitelman's syndrome, 826
- in renal transplantation with severe recurrent bacterial infections, 948
- serum, in maintenance HD patients, 585
- total, *see* Total protein
- urinary excretion of, with TI lesions, 487; *see also* Proteinuria
- see also* Protein catabolic rate in HD patients
- Protein catabolic rate (Pcr) in HD patients
- in chronic intermittent hemodialysis patients, determination of, 887-895
- and IDWG, 579-583
- normalized, with uremic pruritus, 413-419
- Proteinase(s), distribution of proteinase 3 and elastase granulocyte serine, in GN, 253-261
- Proteinase 3, distribution of, in GN, 253-261
- Proteinuria
- effects of flaxseed and flax oil diets on, in 5/6 nephrectomy, 323, 324
- in MGN, 375-379
- in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 223
- in primary FSGS, 535-538
- and urinary Fe speciation in NS, 314-319
- see also* Albuminuria; Microalbuminuria in DM
- Protoporphyrin, zinc, and need for iron therapy in HD, 426-432
- Protrusion acetabuli, osteogenesis imperfecta and, 489-491
- Proximal tubulopathy, nonacidotic, with absorptive hypercalciuria, 222-227
- Pruritus, uremic, dialysis efficacy and improvement of, 413-419
- Pseudomonas peritonitis (PsP) in PD, 769-774
- PTCA (percutaneous transluminal coronary angiography),

- outcome of CABG and, in maintenance HD and/or PD patients, compared, 281-290
- PTH, *see* Parathyroid hormone
- Pulmonary disease, respiratory alkalosis in CAPD patients with, 79-81
- Pulse methylprednisolone for palpable purpura and acute oliguric GN, 652-659
- Pulse oral calcitriol, limitations of, in CAPD patients, 291-296
- Puromycin, AVP gene expression in NS induced by, 58-62
- Purpura  
   Henoch-Schönlein, *see* Henoch-Schönlein purpura  
   palpable, and acute oliguric GN, 651-659  
   thrombotic thrombocytopenic, complicating postinfectious GN, 336-339
- Pyrazinamide, effects of, on renal hypouricemia and exercise-induced ARF, 939
- Pyrogens in HD water, 738-750
- Quality of life, health-related, associated with rHbEPO in predialysis chronic renal disease patients, 543-554
- Quality report card on outcome with higher HCT levels, S1:8-11
- Race and ethnicity  
   donor type, allograft survival and, 623-628  
   ESRD and, *see* Race and ethnicity, ESRD and  
   of exercise-induced ARF patients with renal hypouricemia, 942  
   and hypertensive nephrosclerosis, *see* Hypertensive nephrosclerosis  
   and hypokalemic hypertension in Liddle's syndrome, 829-835  
   with polymicrobial peritonitis, 462  
   prevention of progressive nephropathy in nondiabetic African-Americans, 105  
   of primary FSGS patients, 535-538  
   of *Pseudomonas* peritonitis patients, 771  
   of rHbEPO and Fe therapy patients, 434  
   *see also* Race and ethnicity of RRT patients
- Race and ethnicity, ESRD and, 710-721  
   familial predisposition to ESRD in African-Americans with NIDDM, 710-713  
   of HIV-infected ESRD patients on maintenance HD, rHuEPO for, 906  
   incidence of ESRD by age, diabetes and, 714-721  
   LBW hypothesis on racial differences in HTN, NIDDM, and ESRD, 350-356
- Race and ethnicity of RRT patients  
   CABG and PTCA outcome in maintenance HD and/or PD patients and, 284  
   of Canadian RRT patients, 137  
   and completion of ADs by dialysis patients, 263  
   in New Zealand and Australia, 172  
   in U.S., 121, 122, 124-125
- Radiography  
   hand skeletal, with low-Ca dialysate in CAPD, 457  
   *see also* specific conditions
- Radionuclide ventriculogram of severe LVSD in ESRD patients on CAPD, 761-768
- Rapidly progressive glomerulonephritis (RPGN)  
   differential diagnosis of, 651-659  
   proteinase 3 and elastase distribution in, 253-261
- RAS (renal artery stenosis) in PRF, MRA of, 701-709
- RBF (renal blood flow), racial variation in, hypertensive nephrosclerosis and, 212
- Recombinant human erythropoietin (rHbEPO; r-HuEPO)  
   in HIV-infected ESRD patients on maintenance HD, 904-909  
   HRQL associated with, in predialysis chronic renal disease patients, 548-554  
   and intrarenal EME erythropoiesis in renal allograft fine-needle aspirates, 46-50  
   oral Fe therapy with, 433-439  
   *see also* Higher hematocrit levels for dialysis patients
- Recombinant immunoblot assay (RIBA) 3.0 of HCV infection in HD patients, 572-578
- Recurrent bacterial infections, severe, with renal transplantation, CVID in, 947-952
- Recurrent IgA- $\kappa$  (immunoglobulin A- $\kappa$ ) crystalline deposition disease after renal transplantation, 75-78
- Regional differences in Canadian renal transplant recipients' survival, 146, 147, 149
- Rehabilitation of RRT patients  
   in Japan, 163-164  
   in New Zealand and Australia, 172-173  
   in U.S., 129
- Reimbursement  
   RRT, in U.S., 124-125  
   in U.S. general health care system, 124
- Rejection, renal transplant  
   late acute, prognostic value of serum EPO levels in, 775-780  
   TNF- $\alpha$  and IL-1 in, *see* Interleukin-1, biological control of; Tumor necrosis factor- $\alpha$ , biological control of
- Relapse  
   gram-positive peritonitis, in CAPD and CCPD patients, trough serum vancomycin levels and, 611-615  
   systemic vasculitis, 380-389  
   *see also* entries beginning with term: Recurrent
- Remission, complete, in idiopathic membranous glomerulopathy, therapy and, 871
- Renal ablation (nephrectomy), 5/6, effects of flaxseed and flax oil diets in, 320-329
- Renal allografts  
   intrarenal EME in fine-needle aspirates of, 46-50  
   rejection of, *see* Rejection, renal transplant  
   *see also* Allograft survival; Renal transplantation
- Renal alterations, congenital, LBW and, 351-352
- Renal artery stenosis (RAS) in PRF, MRA of, 701-709
- Renal biopsy  
   of FSGS, 535-538  
   of GN, *see* Renal biopsy of GN  
   in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 224  
   as outpatient procedure, 876-878  
   of renal allograft, intrarenal EME and, 46-50  
   *see also* Renal histology and specific conditions
- Renal biopsy of GN  
   with anti-GBM antibody during pregnancy, 331-332  
   of familial GN, 783-785  
   of MPGN associated with HCV infection, 68  
   of postinfectious GN complicated by HUS, 336-339

- Renal blood flow (RBF) in hypertensive nephrosclerosis and racial variation in, 212
- Renal calculi (nephrolithiasis) in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 222-227
- Renal-cardiovascular risk factors, relationship between microalbuminuria in DM and, 109-110
- Renal cells  
effects of sex hormones on, and gender-related differences in chronic renal diseases, 521-522  
proliferation of epithelial, cyst fluid in ADPKD stimulating, 471-477  
sensing of extracellular  $\text{Ca}^{2+}$  by, 506-513
- Renal clearance  
study of, in differentiation between Bartter's syndrome and Gitelman's syndrome, 637-641  
*see also* Urinary excretion
- Renal dysfunction  
ACE inhibitors causing, in patients on long-term lithium therapy, 82-87  
mild-to-moderate hypertension and, 212-214  
*see also specific conditions*
- Renal dysplasia, unilateral, NS and, 88-95
- Renal endothelin-1 (ET-1), reduced renal mass and production of, in chronic renal disease with hypertension, 918-923
- Renal failure, *see* Acute renal failure; Chronic renal failure; Progressive renal failure
- Renal function  
effects of exercise on, 939-940  
flaxseed and flax oil diet effects on, in 5/6 nephrectomy, 324  
measurement of, and prevention of progressive nephropathy, 105  
*see also specific aspects of renal function*
- Renal hemodynamics, and gender-related differences in chronic renal disease progression, 519-520
- Renal histology  
of NS with unilateral renal dysplasia, 92-93  
of primary adult FSGS, prognosis and, 845-852  
of TI lesions, 479-480  
*see also* Renal biopsy
- Renal hypouricemia, prevention of exercise-induced ARF and, with allopurinol, 937-946
- Renal injury  
gender differences in animal studies of, 517-518  
glomerular injury and 5/6 nephrectomy, effects of flaxseed and flax oil diets on, 320-329  
inflammatory, *see* Interleukin-1, biological control of; Tumor necrosis factor- $\alpha$ , biological control of  
*see also specific types of injuries*
- Renal insufficiency, early, markers for, and epidemiologic study of kidney disease, 724
- Renal mass, reduced, and production of renal ET-1, in chronic renal disease with hypertension, 918-923
- Renal microangiopathy in primary APS, captopril and aspirin for, 486-488
- Renal microvasculature, effects of hypertension on, 211
- Renal osteodystrophy in CAPD  
low-Ca dialysate and, 452-460  
and pulse oral calcitriol, 291-296
- Renal phospholipids, effects of flaxseed and flax oil diets on clearance of, in 5/6 nephrectomy, 323-324, 326, 327
- Renal plasma flow (RPF) in hypertension, effects of oral  $\text{CaCO}_3$  on, 914
- Renal replacement therapy (RRT) registry(ies), 113-205  
Canadian, 134-150  
of different countries, compared, 115-117  
European Dialysis and Transplantation Association-European Renal Association Registry, 176-187  
French, 188-195  
impact of political and socioeconomic factors on RRT programs and, 117-118  
Japanese, 151-164  
Lombard, 196-205  
New Zealand and Australia, 165-175  
U.S., 119-133
- Renal size, and gender-related differences in chronic renal disease progression, 518
- Renal stones (nephrolithiasis) in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 222-227
- Renal survival in idiopathic membranous glomerulopathy, therapy and, 869-870
- Renal transplantation  
in Canada, 140  
in France, 190-192  
HCV infection in, *see* Renal transplantation, HCV infection in  
hypothyroidism and, acute CsA nephrotoxicity and, 503-505  
in Japan, 153-154, 162-163  
lovastatin and nicotinic acid effects in, 616-622  
patient survival with, *see* Patient survival with renal transplantation  
pregnancy and, 465-470  
recurrent IgA- $\kappa$  crystalline deposition disease after, 75-78  
with severe recurrent bacterial infections, agammaglobulinemia in, 947-951  
urologic cancers in recipients of, 696  
in U.S., 125, 128  
*see also* Renal allografts
- Renal transplantation, HCV infection in, 8-12  
concurrent HBV infection with, 10  
in HCV-infected recipient, 10-11  
for HD patients with chronic HCV and/or HBV infection, IFN- $\alpha$  facilitating, 40-45  
serology of, 9  
transmission of, 8-9  
and transplant evaluation of anti-HCV-positive ESRD patient, 11-12  
viral RNA detection of, 9-10
- Renal tubules, *see entries beginning with term: Tubular and element: Tubulo-*
- Renal vasculitis  
proteinase 3 and elastase distribution in GN and, 253-261  
TNF- $\alpha$  and IL-1 in, *see* Interleukin-1, biological control of; Tumor necrosis factor- $\alpha$ , biological control of
- Renal vein thrombosis (RVT), thrombolytic therapy of, 801-806
- Renin, *see* Plasma renin; Renin-angiotensin system; Serum renin
- Renin-angiotensin system, and gender-related differences in chronic renal disease progression, 522



- Respiratory alkalosis in CAPD patients with pulmonary disease, 79-81
- Retinol (vitamin A<sub>1</sub>) in CRF and ESRD during HD, 566
- Reuse of dialyzers, *see* Dialyzer reuse
- rhEPO (r-HuEPO), *see* Recombinant human erythropoietin
- Rheumatoid factors, and cryoglobulinemic GN, 361-369
- RIBA (recombinant immunoblot assay) 3.0 of HCV infection in HD patients, 572-578
- Ribonucleic acid, *see* RNA
- Risk and risk factors
- of allograft loss with LRDs and cadaveric donors, 626
  - cardiovascular, *see* Cardiovascular risk factors
  - for ESRD, epidemiologic study and, 726-729
  - familial, for hypertensive nephrosclerosis, 218
  - and prognosis of HD patients, 405-412
  - see also* Familial predisposition and specific risk factors
- RNA (ribonucleic acid)
- HCV, *see* RNA, HCV
  - hypothalamic AVP messenger, in puromycin-induced NS, 60
- RNA (ribonucleic acid), HCV
- detection of, 9-10, 572-578
  - prevalence of, in cryoglobulinemic GN, 365
- RPF (renal plasma flow) in hypertension, effects of oral CaCO<sub>3</sub> on, 914
- RPGN, *see* Rapidly progressive glomerulonephritis
- RRT, *see* Renal replacement therapy registry(ies) and specific forms of renal replacement therapies; for example: Hemodialysis
- RVT (renal vein thrombosis), thrombolytic therapy of, 801-806
- Saccular aneurysms, intracranial, ADPKD and, 70-74
- SBP (systolic blood pressure), *see* Blood pressure
- Schönlein-Henoch purpura, *see* Henoch-Schönlein purpura
- Sclerosis, *see* Glomerulosclerosis; Hypertensive nephrosclerosis
- Screening, *see* Diagnosis and detection
- Secondary hyperparathyroidism in CRF, *see* Chronic renal failure, secondary HPHT and
- Secondary oxalosis in HD patient, 491-497
- Sepsis
- acute postinfectious GN, proteinase 3 and elastase distribution in, 253-261
  - long-term tunnelled silicone catheter-related, guidewire exchange in management of, 593-596
  - see also* Septic shock and specific infections
- Septic shock, TNF- $\alpha$  and IL-1 in, *see* Interleukin-1, biological control of; Tumor necrosis factor- $\alpha$ , biological control of
- Serine proteinases, distribution of proteinase 3 and elastase granulocyte, in GN, 253-261
- Serologic detection of HCV infection, 4-5, 9
- Serum albumin
- and cardiac function in dialysis patients, S1:5
  - and death during first 90 days of dialysis, 278
  - in HD patients, *see* Serum albumin in HD patients
  - in MGN, 377
  - in nondialyzed CRF patients, 889
  - in puromycin-induced NS, 59
- Serum albumin in HD patients
- and IDWG, 579-583
  - prognosis and, 407
- Serum aldosterone in hypokalemic hypertension, 830
- Serum aluminum (Al)
- and hypervitaminosis A in HD patients, 347
  - and low-Ca dialysate in CAPD, 454-455
- Serum Ca (calcium)
- in Bartter's and Gitelman's syndromes, 638
  - and low-Ca in CAPD, 454-455
- Serum catecholamines in hypokalemic hypertension, 830
- Serum Cl (chloride)
- in Bartter's and Gitelman's syndromes, 638
  - in hypokalemic hypertension, 830
- Serum cortisol in hypokalemic hypertension, 830
- Serum creatinine (Cr; CRE)
- of chronic renal disease patients on rhEPO therapy, 550
  - and death during first 90 days of dialysis, 278
  - in diabetic CRF, nifedipine effects on PMNL function and, 441
  - in hypertension, effects of oral CaCO<sub>3</sub> on, 914
  - in hypokalemic hypertension, 830
  - and late acute rejection of renal transplant, 776
  - in maintenance HD patients, 585
  - in MGN, 377
  - of outpatients undergoing renal biopsy, 877
  - in transplant recipients, lovastatin and nicotinic acid effects on, 617
- Serum dopamine (D) in hypokalemic hypertension, 830
- Serum epinephrine (E) in hypokalemic hypertension, 830
- Serum erythropoietin (EPO), prognostic value of levels of, in late acute rejection of renal transplant, 775-780
- Serum Fe (iron) in HIV-infected patients on maintenance HD, 906
- Serum ferritin in HIV-infected patients on maintenance HD, 906
- Serum HCO<sub>3</sub> (bicarbonate), and death during first 90 days of dialysis, 278
- Serum high-density lipoprotein (HDL)-cholesterol, effects of maintenance HD dialysate buffer composition on concentration of, 584-588
- Serum 18-hydroxycorticosterone in hypokalemic hypertension, 830
- Serum K (potassium)
- in Bartter's and Gitelman's syndromes, 638
  - and death during first 90 days of dialysis, 278
  - in hypertension, effects of oral CaCO<sub>3</sub> on, 914
  - in hypokalemic hypertension, 830
- Serum Mg (magnesium) in Bartter's and Gitelman's syndromes, 638
- Serum Na (sodium)
- in Bartter's and Gitelman's syndromes, 638
  - in hypertension, effects of oral CaCO<sub>3</sub> on, 914
  - in hypokalemic hypertension, 830
- Serum norepinephrine (NE) in hypokalemic hypertension, 830
- Serum P (phosphate), and low-Ca dialysate in CAPD, 454-455
- Serum parathyroid hormone (PTH) in diabetic CRF, nifedipine effects on PMNL function and, 441
- Serum phosphorus in Bartter's and Gitelman's syndromes, 638



- Serum protein in maintenance HD patients, 585
- Serum renin in hypokalemic hypertension, 830
- Serum transaminases, as marker of HCV infection, 6
- Serum urea in maintenance HD patients, 585
- Serum vancomycin, levels of trough, and gram-positive peritonitis relapse in CAPD and CCPD patients, 611-615
- Severe acute renal failure (ARF) in AIDS, outcome of, 390-398
- Severe bacterial infections, recurrent, in renal transplantation, agammaglobulinemia in, 947-951
- Severe hyperparathyroidism, neonatal, extracellular  $\text{Ca}^{2+}$ -sensing receptor in, 506-513
- Severe left ventricular systolic dysfunction (LVSD), CAPD for ESRD with, 761-768
- Sex
- of ARF patients, *see* Sex of ARF patients
  - and cardiac function in dialysis patients, S1:5
  - of chronic renal disease, *see* Sex of chronic renal disease patients
  - of ESRD patients, *see* Sex of ESRD patients
  - of familial ADPKD subjects, mortality and, 372
  - of HCV infection patients on chronic dialysis, 401
  - of idiopathic membranous glomerulopathy patients, 865
  - of MPGN patients with primary Sjögren's syndrome, 635
  - of outpatients undergoing renal biopsy, 877
  - of primary FSGS patients, 535-538
  - of RRT patients, *see* Sex of RRT patients
  - of type II diabetes patients, 839
- Sex of ARF patients, 64
- of AIDS patients with severe ARF, 392, 393
  - of exercise-induced ARF patients with renal hypouricemia, 942
- Sex of CAPD patients
- and low-Ca dialysate, 454
  - with polymicrobial peritonitis, 462
  - with urologic cancers, 696, 697
- Sex of chronic renal disease patients
- and progression of disease, *see* Chronic renal disease progression, gender-related differences in
  - on rhEPO therapy, 550
- Sex of ESRD patients
- HIV-infected, and on maintenance HD, rHuEPO for, 906
  - pentosidine and, 446, 448
- Sex of HD patients
- aminoguanidine pharmacokinetics and, 422
  - with atherosclerotic vascular diseases, 35
  - BP and, and prognosis, 407
  - with chronic HCV and/or HBV infection on IFN- $\alpha$  therapy, 43
  - with diabetic CRF, nifedipine effects on PMNL function and metabolism and, 441
  - with ESRD, pentosidine and, 446, 448
  - of maintenance HD patients, 585
  - oxalosis and, 496
  - on rhEPO and Fe therapy, 434
  - with uremic pruritus, 416
  - with urologic cancers, 696, 697
- Sex hormones, and gender-related differences in chronic renal disease progression, 521-524
- direct cellular effects of sex hormones, 521-522
  - role of estrogen in, 523-524
- Sex of RRT patients
- and completion of ADs by dialysis patients, 401
  - of PD patients with *Pseudomonas* peritonitis, 771
  - as risk factor for survival in Lombardy, 201
  - in U.S., 121, 127
  - see also* Sex of CAPD patients; Sex of HD patients; Sex of transplant recipients
- Sex of transplant recipients
- allograft erythropoiesis and, 49
  - and lovastatin and nicotinic acid effects on hyperlipidemia and hypercholesterolemia, 617
- Shear-induced platelet aggregation (SIPA) in uremia, effects of HD on, 555-563
- Shock, septic, TNF- $\alpha$  and IL-1 in, *see* Interleukin-1, biological control of; Tumor necrosis factor- $\alpha$ , biological control of
- Side effects
- of idiopathic membranous glomerulopathy therapy, 871
  - of nicotinic acid therapy, 620
  - of rhEPO and Fe therapy, 437
- Silicone catheters
- double-lumen, percutaneous translumbar IVC cannulation with, in HD, 732-737
  - long-term tunnelled, guidewire exchange in management of sepsis related to, 593-596
- SIPA (shear-induced platelet aggregation) in uremia, effects of HD on, 555-563
- Sjögren's syndrome, primary, MPGN with, 632-636
- Skeletal radiography, hand, low-Ca dialysate in CAPD and, 457
- Smoking
- as factor associated with urinary albumin excretion in type II diabetes, 838-840
  - by HD patients, prognosis and, 407
- Socioeconomic factors
- comparative impact of, on RRT programs, 117-118
  - in Japanese RRT, 154-156
- SOD (superoxide dismutase), effects of, on endotoxin-induced ARF, 51-57
- Sodium, *see* Na (and  $\text{Na}^+$ )
- Solutes
- clearance of, and rhEPO therapy, S1:12-13
  - see also specific solutes*
- Spent dialysate, total, collection of representative fraction of, 810-812
- Spontaneous vertebral artery aneurysm dissection, as complication of ADPKD, 70-74
- Stenosis
- renal artery, in PRF, MRA of, 701-709
  - superior vena cava, and thrombus formation in double-lumen catheter, 597-602
- Steroids
- for primary FSGS, 534-541
  - for recurrent IgA- $\kappa$  crystalline deposition disease after renal transplantation, 75-78
  - see also specific steroids*
- Superior vena cava stenosis, and thrombus formation on double-lumen catheter, 597-602
- Superoxide ( $\text{H}_2\text{O}_2$ ) production by peritoneal macrophages in CAPD, low-Ca dialysate and, 754, 755
- Superoxide dismutase (SOD), effects of, on endotoxin-induced ARF, 51-57

## Survival

renal, in idiopathic membranous glomerulopathy, therapy and, 869-870

*see also* Allograft survival and entries beginning with terms: Patient survival

Systemic vasculitis, relationship between ANCA concentration and activity of, 380-389

Systolic blood pressure, *see* Blood pressure

Systolic dysfunction, severe left ventricular, CAPD for ESRD with, 761-768

T lymphocytes in TI lesions, 478-488

TCFER (transcapillary fluorescein escape route), plasma fluorescein binding by albumin and, in DM-associated ESRD, 543-547

## Therapy and management

ACE inhibitor, *see* Angiotensin-converting enzyme inhibitor(s)

aminoguanidine, pharmacokinetics of, in diabetic ESRD patients on HD, 420-425

antihypertensive, *see* Hypertension management of Bartter's syndrome, 815-816

CaCO<sub>3</sub>, *see* CaCO<sub>3</sub>

cyclophosphamide, *see* Cyclophosphamide

dietary, *see* Diet; Nutrition

furosemide and thiazide, of Bartter's and Gitelman's syndromes, 637-641

of HCV infection in ESRD patients, 8; *see also* Interferon- $\alpha$  for HCV infection

of idiopathic membranous glomerulopathy, reviewed, 862-875

for IL-1-mediated injury, 959

intrathecal morphine, for LPHS, 629-631

iron, *see* Fe therapy

IVIg, ARF associated with, 228-234

of long-term tunnelled silicone catheter-related sepsis, 593-596

lovastatin and nicotinic acid, in renal transplantation, 616-622

of microalbuminuria in DM, 110-111

for modulation of TNF- $\alpha$  activity, 958

of MPGN with primary Sjögren's syndrome, 635

nifedipine, effects of, on PMNL function and metabolism in diabetic CRF, 440-444

preventive, *see* Prevention

primary FSGS, 543-542

pulse oral calcitriol, limitations of, in CAPD patients, 291-296

renal replacement, *see* Renal replacement therapy registry-(ies) and specific renal replacement therapies

of respiratory alkalosis in CAPD patient with pulmonary disease, 81

rhEPO, *see* Recombinant human erythropoietin

steroid, *see* Steroids

systemic vasculitis, 381

thrombolytic, of RVT, 801-806

ticlopidine, AIN induced by, 934-936

Thiazides in Bartter's and Gitelman's syndromes, 637-641

Thrombocytopenic purpura, thrombotic, complicating GN, 336-338

Thrombolytic therapy of RVT, 801-806

## Thrombosis

renal vein, thrombolytic therapy of, 801-806

thrombus formation on double-lumen catheters, IVUS imaging of, 597-602

Thrombotic thrombocytopenic purpura (TTP) complicating postinfectious GN, 336-339

Thromboxane B<sub>2</sub> (TXB<sub>2</sub>)

and SIPA in uremic patients on HD, 558, 559

urinary, effects of flaxseed and flax oil diet effects on, in 5/6 nephrectomy, 324

TI lesions, *see* Tubulointerstitial lesions

Ticlopidine, AIN induced by, 934-936

## Time on CAPD

and effects of pulse oral calcitriol, 292

for ESRD, HCV infection and, 6

low-Ca dialysate and, 454

urologic cancers and, 697

## Time on dialysis

on CAPD, *see* Time on CAPD

with diabetic CRF, nifedipine effects on PMNL function and metabolism and, 441

on HD, *see* Time on HD

and rhEPO and Fe therapy, 434

## Time on HD

uremic pruritus and, 416

urologic cancers and, 697

Tissue advanced glycation end-products (AGEs), dialysis modality for ESRD and concentrations of, 445-451

Tissue pentosidine, dialysis modality for ESRD and concentration of, 445-451

TNF- $\alpha$ , *see* Tumor necrosis factor- $\alpha$ , biological control of  $\alpha$  (alpha) and  $\gamma$  (gamma) Tocopherol in CRF and ESRD during HD, 566

Total Ca (calcium), plasma, in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 224

## Total cholesterol

in hypertension, effects of oral CaCO<sub>3</sub> on, 914

in type II diabetes, 838

Total CO<sub>2</sub> (carbon dioxide)

in hypokalemic hypertension, 830

in metabolic alkalosis, 344

## Total protein

in CRF and ESRD during HD, 566

in hypertension, effects of oral CaCO<sub>3</sub> on, 914

Total spent dialysate, collection of representative fraction of, 810-812

Trade-off hypothesis of secondary HPTH in CRF, *see* Chronic renal failure, trade-off hypothesis of secondary HPTH in

Transaminases, serum, as marker of HCV infection, 6

Transcapillary fluorescein escape route (TCFER), plasma fluorescein binding by albumin and, in DM-associated ESRD, 543-547

Transferrin, and urinary Fe speciation in NS, 314-319

Transfusions, *see* Blood transfusions

Translumbar inferior vena cava (IVC) cannulation, percutaneous, with double-lumen silicone catheters in HD, 732-737

Transluminal coronary angioplasty, percutaneous, outcome of CABG and, in maintenance HD and/or PD patients, compared, 281-290

- Transmission of HCV infection, 6-8  
to ESRD patients, *see* Transmission of HCV infection to ESRD patients  
to transplant recipients, 8-9
- Transmission of HCV infection to ESRD patients through blood transfusions, 5-6  
dialysis staff-to-patient, 6  
nosocomial, 7-8
- Transplantation, *see* Renal transplantation
- Triamterene for hypokalemic hypertension of Liddle's syndrome, 829-825
- Triglycerides  
in CRF and ESRD during HD, 566  
effects of flaxseed and flax oil diets on, in 5/6 nephrectomy, 323  
lovastatin and nicotinic acid effects on, in renal transplantation, 617  
in maintenance HD patients, dialysate buffer composition and, 586  
in type II diabetes, 839
- Triphosphatase, Na<sup>+</sup>,K<sup>+</sup> adenosine, in hypertensive nephrosclerosis, racial variations in, 212
- Triphosphate, adenosine, in diabetic CRF, effects of nifedipine on, 440-444
- Trough serum vancomycin, levels of, and gram-positive peritonitis relapse in CAPD and CCPD patients, 611-615
- TTP (thrombotic thrombocytopenic purpura) complicating postinfectious GN, 336-339
- Tubular disorders in Bartter's syndrome, *see* Bartter's syndrome
- Tubular function in renal hypouricemia and exercise-induced ARF, 938-939
- Tubular ion transport, Bartter's syndrome due to disorders of, 818-819
- Tubular necrosis, *see* Acute tubular necrosis
- Tubular vacuolization, IVIg therapy and, 228-234
- Tubulointerstitial damage in chronic renal disease, renal ET-1 production and, 918-923
- Tubulointerstitial (TI) lesions  
in MGN, proteinuria and, 375-379  
in young subjects, 478-488
- Tubulopathy, proximal, nonacidotic, with absorptive hypercalciuria, 222-227
- Tumefactive megalocytic interstitial nephritis with *E coli* bacteremia, 928-933
- Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), biological control of, 954-958  
with anti-inflammatory interleukins, 961  
cellular effects of, 955  
regulation of TNF- $\alpha$  bioactivity and, 957-958  
structure and function of, 954-955  
summary on, 961-962  
therapeutic modulation of TNF- $\alpha$ , 958  
of TNF- $\alpha$  receptors, 955-957
- Tunneled silicone catheter, long-term, guidewire exchange in management of sepsis related to, 593-596
- TXB<sub>2</sub>, *see* Thromboxane B<sub>2</sub>
- Type I diabetes mellitus, *see* Diabetes mellitus
- Type II diabetes mellitus, *see* Non-insulin-dependent diabetes mellitus
- Type II membranoproliferative glomerulonephritis (MPGN),  
paramesangial glomerular deposits in, correlated with hypocomplementemia, 853-861
- Type IV collagen, distribution of, in GN, 680-688
- Ultrasound (US), intravascular, of thrombus formation on double-lumen catheter, 597-602
- Unilateral renal dysplasia, NS and, 88-95
- United States (U.S.), RRT in, 119-133
- United States Renal Data System (USRDS), RRT data of, 119-133
- Urate, *see* Fractional urate excretion
- Urea  
mass transfer area coefficient for, during APD, 605  
serum, in maintenance HD patients, 585  
*see also* Kt/V urea and entries beginning with term: Urea  
Urea generation rate, and Pcr in nondialyzed CRF patients, 887-895
- Urea nitrogen  
blood, *see* BUN  
in hypertension, effects of oral CaCO<sub>3</sub> on, 914  
levels of, in collected fractions of total spent dialysate, 811
- Urea output, and Pcr in nondialyzed CRF patients, 887-895
- Urea rebound  
high-flux HD efficiency and, 26-29  
and Pcr in nondialyzed CRF patients, 887-895
- Uremia, 689-700  
due to HAN, disappearance of, 689-693  
shear-induced platelet aggregation in, effects of HD on, 555-563  
urologic cancers in, 694-700  
*see also* Chronic renal failure and entries beginning with term: Uremic
- Uremic pruritus, dialysis efficacy and improvement of, 413-419
- Uremic syndrome, hemolytic, complicating acute postinfectious GN, 336-339
- Uric acid  
in CRF and ESRD during HD, 566  
lovastatin and nicotinic acid effects on, in renal transplantation, 617  
plasma, in nonacidotic proximal tubulopathy with absorptive hypercalciuria, 223  
*see also* Hyperuricemia; Hypouricemia
- Urinary excretion  
of aldosterone, catecholamines, metanephrines, VMA, and cortisol in hypokalemic hypertension, 830  
Ca, in Bartter's and Gitelman's syndromes, 638  
Cr, *see* Creatinine and creatinine clearance  
Fe, speciation of, in NS, 314-319  
fractional, *see* Fractional excretion  
K, in Bartter's and Gitelman's syndromes, 638  
of kallikrein, racial variation in, hypertensive nephrosclerosis and, 212  
Na, *see* Urinary excretion, Na  
protein, with TI lesions, 481; *see also* Albuminuria; Microalbuminuria in DM; Proteinuria  
renal ET-1, in chronic renal disease with reduced renal mass, 918-923  
TXB<sub>2</sub> and 6-keto PGF<sub>1 $\alpha$</sub> , flaxseed and flax oil diet effects on, in 5/6 nephrectomy, 324, 327  
*see also* entries ending with suffix: -uria

- Urinary excretion, Na  
   in Bartter's and Gitelman's syndromes, 638  
   racial variation in, hypertensive nephrosclerosis and, 212
- Urinary obstruction, and severe ARF in AIDS, 390-398
- Urologic cancers in uremia, 694-700
- U.S. (United States), RRT in, 119-133
- US (ultrasound), intravascular, of thrombus formation on double-lumen catheter, 597-602
- USRDS (United States Renal Data System), RRT data of, 119-133
- Vacuolization, tubular, IVIg therapy and, 228-234
- Vancomycin, levels of trough serum, and gram-positive peritonitis relapse in CAPD and CCPD patients, 611-615
- Vanillylmandelic acid (VMA), urinary excretion of, in hypokalemic hypertension, 830
- Vasoactive agents, influence of sex hormones on synthesis and release of, 521
- Vascular access  
   adapting, to higher HCT levels, S1:13-14  
   clotting by heparin of, 642-647  
   correlation between venography, venous pressure and, 269-274  
   *see also* Double-lumen catheters; Silicone catheters
- Vascular access blood flow (BF), angiodynography of, 22-25
- Vascular diseases, atherosclerotic, in HD patients, ankle-arm BP as marker for, 34-39
- Vascular hyporesponsiveness in Bartter's syndrome, 816-817
- Vasculitis, *see* Renal vasculitis; Systemic vasculitis
- Vasopressin, arginine vasopressin gene expression in puromycin-induced NS, 58-62
- Vena cava  
   inferior, percutaneous translumbar cannulation of, with double-lumen silicone catheters in HD, 732-737  
   superior, stenosis of, and thrombus formation on double-lumen catheter, 597-602
- Venography, correlation between venous pressure, hemoaccess function and, 269-274
- Venous pressure, correlation between venography, hemoaccess function and, 269-274
- Venovenous hemodiafiltration, continuous, in infants and children, 17-21
- Ventricular systolic dysfunction, severe left, CAPD for ESRD with, 761-768
- Ventriculogram, radionuclide, of severe LVSD in ESRD patients on CAPD, 761-768
- Vertebral artery aneurysm dissection, spontaneous, as complication of ADPKD, 70-74
- Viral DNA (deoxyribonucleic acid) detection, HCV, 4, 5
- Visceral perforation, and pneumoperitoneum in PD patients, 297-301
- Vitamin(s) in parenteral nutrition for ARF, 101
- Vitamin A, hypervitaminosis A in HD patients, 346-348
- Vitamin A<sub>1</sub> (retinol) in CRF and ESRD during HD, 566
- Vitamin C (ascorbic acid) in CRF and ESRD during HD, 564-571
- Vitamin D  
   impaired metabolism of, in secondary HPTH in CRF, 668-672  
   *see also* specific vitamin D metabolites
- Vitronectin in GN  
   distribution of, 680-688  
   in familial GN, 781-791
- VMA (vanillylmandelic acid), urinary excretion of, in hypokalemic hypertension, 830
- Water, HD, quality of, 738-750
- Wegener's granulomatosis (WG), proteinase 3 and elastase distribution in, 253-261
- Weight, *see* Body weight; Weight gain
- Weight gain, interdialytic, and nutrition in HD patients, 579-583
- WG (Wegener's granulomatosis), proteinase 3 and elastase distribution in, 253-261
- White Americans, *see* Race and ethnicity
- Women  
   incidence rates of ESRD attributed and not attributed to DM in, 716-718  
   *see also* Pregnancy; Sex
- Work status, and completion of ADs by dialysis patients, 263
- X-ray, chest, of PD patients with pneumoperitoneum, 297-301
- Young subjects, TI lesions in, 478-488
- Zinc (Zn) in HD patients with uremic pruritus, 416
- Zinc protoporphyrin (ZPP), and need for iron therapy in HD, 426-432

